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 Volumetric muscle loss (VML) in skeletal muscle and loss of cardiac function after myocardial 
infarction lack viable treatment options for functional tissue restoration. Previously investigated 
strategies such as synthetic graft placement and cell therapy are limited in their ability to restore 
function to these tissues. Biologic scaffolds composed of extracellular matrix (ECM) have been 
prepared from numerous source tissues including small intestine, urinary bladder, liver, and 
dermis. When properly prepared, ECM scaffolds implanted into a site of injury are rapidly 
infiltrated by host cells, subjected to degradation, and often remodel into site appropriate host 
tissue. The ECM of tissues and organs represents the secreted products of resident cells, a 
process which provides a unique microenvironmental niche that influences cell behavior during 
homeostasis and injury. The objective of the present study was to develop and characterize 
muscle tissue specific scaffolds composed of skeletal (M-ECM) and cardiac muscle (C-ECM), 
and to determine whether a muscle tissue ECM scaffold preferentially promotes muscle 
restoration compared to non-muscle ECM. 
 A method of skeletal and cardiac muscle decellularization was developed that efficiently 
removed cells while preserving native ECM components, including basement membrane 
proteins, glycosaminoglycans, and growth factors. Degradation products produced by pepsin 
digestion of M-ECM, C-ECM, and non-muscle ECM derived from small intestinal submucosa 
(SIS-ECM) decreased proliferation and promoted the myogenic differentiation of perivascular 
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stem cells in vitro. Although M-ECM was more rapidly degraded than both C-ECM and SIS 
ECM, all ECM scaffolds showed a similar increase in functional skeletal myogenesis.  
These studies show that M-ECM and C-ECM can be prepared in a manner that preserves muscle 
ECM specific components and biologic activity. M-ECM promoted stem cell myogenic activity 
in a non-tissue specific manner in vitro, and both muscle and non-muscle ECM promoted 
functional myogenesis to a similar extent in vivo. These results indicate that M-ECM is not a 
preferred substrate for skeletal muscle remodeling compared to C-ECM and SIS-ECM.       
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1.0  INTRODUCTION 
1.1 SKELETAL AND CARDIAC MUSCLE INJURY  
1.1.1 Clinical incidence and significance of muscle injury 
Volumetric muscle loss injuries and loss of cardiac function after myocardial infarction are two 
conditions that currently lack viable treatment options for functional tissue restoration. Coronary 
heart disease, defined as the narrowing of the coronary vessels that perfuse the heart, currently 
affects approximately 16.3 million Americans, and is the primary precursor to myocardial 
infarction. There are 610,000 new myocardial infarctions each year costing $297 billion in direct 
and indirect medical costs, reflecting a dire need for effective treatments [1]. Cardiac tissue is 
irreversibly damaged during infarct events, resulting in a loss of cardiac function, which is then 
followed by further tissue degeneration in a remodeling process that persists for weeks [2, 3]. 
Most pharmacological and surgical treatments for infarctions focus on improving coronary 
perfusion to minimize further damage, and do not directly address restoration of previously lost 
function. Left ventricle dilation may be mitigated by the placement of a nondegradable synthetic 
patch (e.g. Dacron or polytetrafluoroethylene), which prevents further dilation but does not 
restore function [4, 5]. Currently, the only successful treatments for endstage heart failure are 
heart transplantation or ventricular assist device implantation, though there is a critical shortage 
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in the number of available donor hearts [6, 7] and assist devices are only able to offer temporary 
support [8, 9].  
Volumetric muscle loss (VML) is defined as the loss of a sufficiently large fraction of a 
skeletal muscle body such that natural regeneration mechanisms are unable to compensate, 
resulting in a permanent loss of function [10]. Traumatic injuries such as car accidents and 
gunshot wounds are frequent causes in the civilian setting [11-14], though surgical removal of 
large volumes of skeletal muscle during tumor resection or after muscle necrosis due to ischemia 
may also occur [11, 15].  However, incidences of VML are considerably greater in the active 
military population where high energy impact trauma to the extremities represent the greatest 
proportion of combat casualties [10, 16-20].  Advances in body armor have greatly reduced the 
incidence of fatal penetrating wounds to the chest and abdomen, though as a result, extremity 
injuries in surviving soldiers have increased. Blast injuries from improvised explosive devices 
(IEDs) are one such cause [16]. These can be highly dynamic and complex injuries involving 
multiple tissue types, and in combination with a lack of expedient hospital care on the battlefield, 
creates the potential for devastating soft tissue loss with significant financial consequences [21-
25]. In addition to direct tissue loss from the trauma, VML may occur from indirect conditions 
such as peripheral compartment syndrome (PCS) in both civilian and military populations [26-
30]. PCS develops following muscle trauma, resulting in edema and/or bleeding within the 
enclosed muscle compartment causing an increase in muscle compartment pressure. This 
pressure eventually exceeds capillary perfusion pressure, which leads to muscle ischemia and 
necrosis necessitating muscle removal to salvage the limb [28].   
Currently, the most common clinical treatment for extremity muscle loss is a muscle 
autograft transplant to the injury site, such as a free flap transfer procedure [11, 13, 14, 16-18, 
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20, 31-33]. However, this treatment is limited by the size of the muscle graft that can be 
successfully incorporated into the recipient site (innervated and vascularized) without necrosis, 
functional differences between the donor and recipient muscles, and significant donor site 
morbidity [31, 32]. Muscle defects in the abdominal wall or diaphragm are often repaired with 
synthetic, nondegradable mesh materials (e.g. polypropylene or Dacron), though these synthetic 
materials elicit a chronic foreign body response and fibrosis with no functional recovery of the 
injured muscle serving only to reinforce the remaining tissue to prevent further damage [34-36].  
Both skeletal and cardiac muscle injuries are debilitating and potentially life threatening. 
The primary function of both tissues on the cellular level is force production, and both tissues 
possess similar intracellular contractile machinery and regulatory mechanisms to translate 
neuronal stimuli to usable force. Though how these tissues utilize this force differs considerably. 
Skeletal muscle is primarily responsible for locomotion, as well as breathing and stabilization; 
loss function consequently leads to reduced mobility and independence. Cardiac tissue on the 
other hand, utilizes this force to generate cyclic pressure and flow to maintain blood circulation. 
Alternative clinical strategies are therefore required to restore meaningful function in both 
cardiac and skeletal muscle tissues following injury. Regenerative medicine approaches to 
muscle injury are being investigated to promote new muscle tissue growth rather than only 
focusing on preventing further tissue damage.  
1.1.2 Skeletal muscle injury response 
Skeletal muscle regeneration following injury has been well characterized in in humans and 
animals. Unlike other tissues, such as the central nervous system [37, 38], skeletal muscle has a 
relatively robust regenerative capacity [39, 40], capable of fully recapitulating normal tissue 
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architecture and function after insult. Established muscle injury models such as cardiotoxin 
injection, cryoinjury, muscle excision, and muscle crush all progress through similar cellular and 
molecular events [39]. Skeletal muscle regenerative pathways are well understood to progress 
through a cascade of differentiation via (1) the activation of resident progenitor cells to commit 
to a differentiated myogenic lineage, (2) proliferation after activation, (3) further myogenic 
differentiation and exit from the cell cycle, and finally (4) fusion into functional multinucleate 
myofibers [39, 40]. These steps are summarized in Figure 1. 
The most abundant and well studied muscle progenitor is the satellite cell, which is 
characterized by the expression of the transcription factor Pax-7 [41-43], and is the primary 
contributor to new muscle fibers following injury. Quiescent satellite cells reside in a well 
defined stem cell niche during homeostasis that is located directly between the myofiber cell 
membrane and the basement membrane of the surrounding extracellular matrix (ECM). Satellite 
cells are the primary source of myofibers during development and after injury; Pax-7 knockouts 
are embryonic lethal and lack skeletal muscle formation, and recent reports of conditional Pax-7 
ablation in adult tissues completely prevents de novo muscle formation, which suggests all 
myogenic cells are required to proceed through a Pax-7+ state during the differentiation cascade 
[43-45]. After stimulus (e.g. injury) satellite cells are activated to undergo asymmetric division. 
One daughter cell retains a relatively undifferentiated state and Pax-7 expression in order to 
maintain the satellite cell pool, while the other daughter cell will differentiate towards a mature 
myogenic phenotype, the skeletal muscle myoblast [40, 42, 43, 46-48]. These myoblasts are 
highly proliferative, and downregulate expression of Pax-7 while upregulating the muscle 
regulatory transcription factors MyoD and Myf5, adhesion molecules such as M-Cadherin, and 
cytoskeletal proteins such as desmin, indicating commitment to myogenic differentiation [39-
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41]. Myoblasts migrate towards sites of damaged muscle and proliferate extensively in response 
to mitogenic factors present in the wound environment, which is comprised of immune cell 
secreted cytokines and chemokines and growth factors secreted by damaged myofibers [49, 50]. 
Further along the muscle regeneration cascade, myoblasts will exit the cell cycle, downregulate 
MyoD and Myf5, and upregulate the transcription factor Myogenin as fully committed muscle 
cells [39-41, 51, 52]. These myogenin+ cells will then align linearly, form cell-cell adhesions 
with neighboring myogenin+ cells, and finally fuse to the pre-existing damaged myofibers or 
form de novo myofibers. Fusion is accompanied by the expression of the late muscle 
differentiation transcription factor MRF4, cytoskeletal proteins such as dystophin and 
dystroglycan, as well as functional contractile proteins such as sarcomeric myosin and skeletal 
muscle tropomyosin. Newly formed myofibers initially display nuclei located within the center 
of the cytoplasm (a remnant of cell fusion), which will eventually migrate towards the myofiber 
periphery during muscle fiber maturity [39]. Other events during final differentiation include 
myofiber hypertrophy, maturity of muscle-ECM adhesion complexes for force transmission, and 
formation of neuromuscular junctions with innervating axons and nervous system control [53, 
54]. Indeed, functional innervation and formation of a stable neuromuscular junction is necessary 
for muscle fiber survival and appropriate phenotype. A lack of muscle fiber innervation and 
neurologic control results in irregular contractile activity and eventually, muscle atrophy [55]. 
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 Figure 1. Overview of the mammalian muscle regeneration cascade following injury. Muscle 
injury activates quiescent Pax7+ stem cells to undergo asymmetric division, and produce 
proliferative MyoD+ myoblasts. Myoblasts continue to proliferate, differentiate and align, and 
fuse to form multinucleate myofibers. The specific time course varies depending upon the extent 
and type of injury as well as the species in which injury occurs.  
 
However, there are circumstances where normal muscle regeneration mechanisms are 
unable to compensate for the injury and muscle regeneration remains incomplete. If the degree of 
injury is sufficiently large, or if there is significant disruption to the muscle ECM, normal muscle 
repair mechanisms are inadequate for complete functional restoration [40, 49]. This is true in 
VML where large muscle masses are removed by trauma or excision, and subsequently only 
partially replaced with fibrous scar and/or adipose tissue rather than new muscle [10, 50, 56]. 
Chronic muscle injury, in which small but repeated muscle damage occurs, results in prolonged 
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tissue healing and scar tissue formation. Certain disease states, such as Duchenne muscular 
dystrophy, follow this pattern due to the constant muscle injury induced by incomplete myofiber 
linkage to the ECM [57]. As stated previously, effective muscle repair is dependent on two 
general cell processes: proliferation of muscle progenitors to create a pool of myogenic cells, and 
differentiation/fusion to become terminally differentiated and functional myofibers. Either or 
both of these processes may be potential targets for directing and improving muscle regeneration. 
1.1.3 Cardiac muscle injury response 
In contrast to skeletal muscle, adult cardiac tissue does not possess a putative progenitor 
cell type as abundant or functional as the skeletal muscle satellite cell, and does not effectively 
regenerate following injury. Ischemia from myocardial infarction and resultant left ventricle 
remodeling is the most well characterized injury response in the heart [2, 3]. The acute ischemic 
injury causes immediate cell death in the infarct region with concomitant loss of function. This 
primary injury mechanism, though it may be relatively minor, initiates a sequence of deleterious 
secondary remodeling events during the following weeks that greatly reduces cardiac function. 
The primary injury will induce a pro-inflammatory environment with recruitment of multiple 
immune cell types, and will eventually undergo myofibroblast mediated remodeling into fibrous 
scar tissue [3]. The loss of contractility in this scar region increases the remaining physical load 
on remaining cardiomyocytes. Like skeletal muscle fibers, cardiomyocytes are terminally 
differentiated and post mitotic, requiring adjacent cardiomyocytes to compensate for this 
increased load via cellular hypertrophy [58]. Consequently, increased stress is applied to the scar 
region, promoting continued remodeling and ultimately dilation to reduce wall stress, which in 
turn increases end diastolic and end systolic volumes.  The hemodynamic load on remaining 
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cardiomyocytes increases, creating a feedback loop between negative remodeling and 
compensatory mechanisms that ultimately leads to abnormal pressure, reduced ejection fraction, 
and potentially heart failure [3]. 
Due to the low frequency and/or ineffectual regenerative response, endogenous cardiac 
regeneration mechanisms in the adult heart are not well understood. Several studies have shown 
that there is cardiomyocyte renewal during homeostasis in adult heart tissue, though at a very 
low rate [58]. Much of our understanding of cardiomyogenesis has been derived from studies 
during fetal development. It is known that differentiating cardiomyocytes express transcription 
factors such as GATA4, Nkx2-5, TBX5, and MEF2C [59], and terminally differentiated 
cardiomyocytes also express sarcomeric myosin and cardiac tropomyosin, analogous to skeletal 
muscle [59, 60]. In vitro studies of cardiomyogenic differentiation models, such as embryonic 
stem cell (ESC) or induced pluripotent stem cell (IPS cell)  differentiation, have shown that early 
expression of these cardiac transcription factors are required for differentiation [61]. Although 
cardiac stem cells have been identified, they may not be numerous enough or are altered by the 
injury microenvironment to successfully overcome the fibrotic pathway [58, 62, 63]. These cells 
have therefore only been extensively studied in in vitro contexts where they can be expanded, 
typically with the goal of implantation for cardiac cell therapy applications [62-65]. The most 
well characterized cardiac stem cell is the c-kit+ stem cell population [64], which has shown 
cardiomyogenic potential in vitro, but has not been observed to participate directly to cardiac 
repair in vivo. So unlike skeletal muscle, enhancement of cardiac stem cell regenerative potential 
is necessary for any degree of regeneration. 
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1.2 EXTRACELLULAR MATRIX (ECM) AS A BIOLOGIC SCAFFOLD 
1.2.1 The role of ECM in tissues and organs 
The extracellular matrix of tissues and organs is composed of a complex milieu of 
proteins and polysaccharides that provides structural, mechanical, and biological support to its 
resident cells. Rather than simply acting as an inert support structure, or “glue” which holds cells 
and tissues together, the ECM is a critical determinant of cell phenotype and function in vivo, 
providing biochemical and biomechanical signals influencing processes such as cell survival, 
proliferation, migration, differentiation, morphology, secretory profile, metabolism, and other 
specialized activities. The ECM in turn is composed of the secreted products of its resident cells, 
creating a feedback loop referred to as “dynamic reciprocity” between the ECM and its resident 
cells. The ECM has been shown to be a critical factor in histogenesis during development, 
homeostasis, and wound healing as well as other biological processes [66, 67].  
Dynamic reciprocity between the ECM microenvironment and resident cells can also be 
involved in disease progression in many organ systems. Liver cirrhosis is an example of the 
progressive remodeling of an ECM to a fibrotic state after repeated chemical or pathogenic 
injury, which then disrupts function and prevents liver regeneration [68]. There is also evidence 
that abnormal ECM composition and organization can contribute to the development of certain 
types of cancer. In some models of breast cancer, tumor formation only occurs when the ECM 
substrate is disrupted regardless of oncogene expression [67]. Studies of breast cancer 
development have shown that tumor ECM consists of an altered composition and disrupted 
organization compared to normal tissue. Such disrupted ECM promotes disregulation of 
mammary epithelial cell proliferation and phenotype to one similar to a ductal cell carcinoma in 
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vitro, and likewise, tumor cells produce tumor ECM. Conversely, tumor cells cultured on normal 
ECM will assume a non-cancerous organization and proliferation rate. This demonstrates that 
ECM-cell signaling is bidirectional [67].   
Skeletal and cardiac muscle ECM also play critical roles in tissue function and disease. 
Mutations in the gene encoding the skeletal muscle ECM protein laminin alpha-2 lead to severe 
muscular dystrophy, which is due to an inability of muscle fibers to efficiently mechanically 
couple with the ECM [69, 70]. As stated previously, skeletal muscle satellite cells anatomically 
reside in a defined niche in direct contact with basement membrane proteins of the muscle ECM, 
and are required to maintain satellite cell quiescence [41, 42].  Cardiac ECM fibrotic remodeling 
is a well characterized event following myocardial infarction [2, 3]. Concomitant with 
cardiomyocyte necrosis is the activation and proliferation of myofibroblasts that contribute to 
cardiac ECM fibrotic remodeling for weeks after the acute infarction event. The replacement of 
contractile cardiac tissue with fibrotic scar not only increases the load on remaining tissue, but 
also results in ventricle wall thinning and dilation, further decreasing cardiac output and 
efficiency.    Therefore, disease state ECM may inhibit regenerative processes by promoting 
further tissue degeneration and loss of function. 
1.2.2 ECM as a biologic scaffold 
The potent biologic signals present in the native ECM make scaffolds composed of these 
materials an attractive option for tissue engineering applications. Indeed, numerous studies have 
shown that ECM scaffolds alter the default wound healing response when implanted in a site of 
injury. ECM scaffolds, which are not chemically crosslinked and devoid of cellular remnants, are 
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rapidly degraded [71, 72] and replaced with well organized site appropriate host tissue, a process 
termed constructive remodeling, rather than default fibrotic scarring pathways [73, 74].  
ECM scaffolds are prepared from decellularized tissues, and have demonstrated efficacy 
in the repair of numerous soft tissues, including urinary bladder [75-78], esophagus [79-83], liver 
[84-86], lung [87-89], and muscular tissues [90-123]. Native xenogeneic and allogeneic tissues 
are decellularized via a series of mechanical, chemical, and/or enzymatic processes to yield an 
acellular scaffold that ideally maintains ECM composition and structure.  
There are several considerations in ECM scaffold production. Adequate decellularization 
has been shown to be a necessary aspect. Whereas ECM proteins are highly conserved among 
mammalian species, non-autologous cells present multiple surface and intracellular antigens that 
would be recognized by the host immune system. For example, the systemic tissue rejection 
response following organ transplation is more accurately rejection of the implanted donor cells, 
and not the ECM [124, 125]. Implanted acellular ECM does induce an immune response, though 
it is primarily via activation of innate immune pathways, which is highly localized to the site of 
implantation [94, 124, 126]. Other considerations involve post processing following 
decellularization, such as chemical crosslinking and sterilization. Crosslilnking is often 
performed to increase ECM mechanical properties and degradation time. However, such 
treatments inhibit natural protoelytic processes that are necessary for remodeling [72, 127, 128].  
There are several factors and mechanisms that can influence the host response to a 
biologic scaffold, including the source tissue and the processing methods used to decellularize 
the tissue. The ECM of numerous tissues and organs have been evaluated for soft tissue repair, 
including dermis, small intestine, urinary bladder, and peritoneum, and each of these tissues are 
prepared using different decellularization techniques to achieve desired scaffold properties. 
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Processing methods that yield adequate decellularization, for example, are one of the key 
parameters to minimizing a pro-inflammatory response and associated poor remodeling 
outcomes that are elicited by necrotic cell fragments remaining in the scaffold [129, 130]. 
Therefore, both the tissue source and decellularization method require optimization for use in 
specific applications such as muscle repair.   
1.2.3 Clinical applications of ECM scaffolds 
ECM scaffold materials have been successfully utilized in numerous clinical applications, 
typically for soft tissue repair as shown in Table 1. Ventral hernia repair is one of the most 
frequent clinical applications of ECM scaffolds. Most surgical mesh devices used for ventral 
hernia repair are composed of synthetic materials with robust mechanical strength, and are 
typically incorporated quickly into the host tissue.[131-136] While these mesh materials provide 
more than enough strength to prevent hernia recurrence, such devices are associated with non-
trivial complications including adhesion, infection, fistula formation, and contraction [136-140]. 
Additionally, the innate immune response to the synthetic materials is classically a chronic pro-
inflammatory foreign body reaction that promotes fibrotic encapsulation. This fibrotic 
encapsulation is associated with long-term patient discomfort, which can lead to revision surgery 
and surgical mesh removal [136, 141]. The intensity of the inflammatory response to an 
implanted mesh may be linked to the degree of tissue ingrowth and scar formation, and 
modulation of this response can have marked downstream effects [142]. Surgical mesh materials 
composed of naturally occurring allogeneic or xenogeneic extracellular matrix (ECM) have been 
used as an alternative to synthetic materials to abrogate the foreign body response, prevent 
infection, and minimize or avoid excessive fibrosis [107, 143-146]. In these circumstances, 
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facilitating a constructive host remodeling response is an advantage to the dense scar tissue 
deposition in the response to synthetic mesh materials [73, 146]. This logic has also justified the 
use of ECM scaffolds in applications such as breast reconstruction, where constructive 
remodeling is preferred to dense scar tissue.   
 
Table 1. Examples of clinical products composed of decellularized tissues. 
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1.3 TISSUE SPECFIC ECM SCAFFOLDS IN TISSUE ENGINEERING 
1.3.1 The tissue specific ECM hypothesis 
There have been several recent studies to suggest that the source tissue of an ECM scaffold is a 
critical determinant of the host remodeling response [74, 84, 85, 88, 147-153]. The ECM of 
every tissue provides resident cells with a unique microenvironmental niche, which is the sum of 
numerous bioactive factors including cell adhesion proteins, glycosaminoglycans, and growth 
factors that are arranged in a tissue specific distribution and architecture. As previously stated, 
the ECM directly affects its resident cell’s phenotype and function, providing numerous biologic 
signals. In turn, the ECM is also remodeled by these resident cells during homeostasis and injury. 
The net effect is a healthy matrix and cell population that are fundamentally linked to each other 
for the maintenance of tissue function.  
The presence of healthy ECM signaling is therefore a critical component of a tissues 
function. It has been hypothesized that ECM scaffold remodeling may benefit from specific 
microenvironmental factors that are retained in the scaffold after tissue decellularization. It may 
be advantageous to utilize the tissue specific bioactive factors found in native tissues via the 
preparation and implementation of homologous ECM scaffolds (i.e. the use of a scaffold 
prepared from the same tissue that it is intended to treat).  
1.3.2 Considerations in evaluating ECM tissue specificity 
Liver [84, 85], lung [88], vascular structures [154], bladder [75, 77], cardiac muscle [121, 123], 
and skeletal muscle [92, 93, 95, 98, 101, 102] have all been evaluated for homologous 
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implementation using a variety of methods. An important distinction to note is how tissue 
specificity is defined. In vitro assays, in which specialized tissue specific cell populations are 
cultured on or within a matched ECM scaffold, are often pertinent to evaluate functional 
characteristics such as transcriptional profile, surface marker expression, morphology, and/or 
protein secretory profile. Another approach is to expose undifferentiated stem cells to ECM to 
determine whether the ECM directs differentiation towards a tissue specific phenotype. In vivo 
functional comparisons may be more challenging, though restoration of function is the ultimate 
goal of an ECM therapy. In some of these cases, animal survival is dependent on immediate 
functional benefit. This would be true for cardiac replacement following heart failure, where 
circulatory support can only be maintained for a limited length of time via artificial means. 
Correspondingly, it would be impractical to implant an acellular scaffold to allow constructive 
remodeling, which may take months for functional cells to repopulate the scaffold. The whole 
organ engineering platform aims to reduce this functional gap by repopulating the decellularized 
organ with autologous host cells and preconditioning the organ in an in vitro bioreactor until the 
tissue reaches functional maturity. This strategy requires homologous ECM transplantation since 
the ECM structure is intrinsically linked to the physiologic function in vivo, and therefore 
comparisons to non-homologous ECM is not possible.  
A potential confounding variable in these studies is the form of the ECM being evaluated. 
Specifically, the form refers to how altered the ECM meso- and macro- architecture is from the 
native state. There are several general classifications of ECM form that are present in the 
literature. These forms include: fully intact ECM (e.g. resulting from whole organ 
decellelularization), ECM sheets, comminuted ECM particulate, and enzymatically solubilized 
ECM (e.g. for ECM hydrogel formation). These final forms can be induced before or after 
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decellularization, i.e. an intact ECM scaffold may be reduced to a particulate for a desired 
application, or a particulate form of the native tissue can be decellularized. The precise approach 
depends on the optimal decellularization method for an application and the investigator’s desired 
goals and applications for the study. A final caveat to this classification of form is that the 
decellularization method will induce some disruption of ECM structure at the micro and, 
potentially, the meso scales. The relevance of these changes must be evaluated on a case by case 
basis.  
1.3.3 Studies that support a tissue specific hypothesis 
1.3.3.1 Lung ECM 
Lung ECM has been among the most well studied sources for tissue specific ECM 
applications. Particulate forms of decellularized alveoli were first isolated by mechanical 
disruption with sonication and detergent treatment by Kuttan et al. [155], which was then 
characterized and shown to retain multiple basement membrane components and 
glycosaminoglycans found in the native ECM. Later work by Lwebuga-Mukasa et al. [156]  
decellularized intact alveoli using only detergent-based methods. Pneumocyte culture on alveolar 
ECM promoted a distinct transition of type II pneumocytes to type I pneumocytes when 
compared to the basement membrane of decellularized amnion, though the significance of this 
transition is questionable since culture on tissue culture plastic produces the same effect. More 
recent studies have also investigated fragmented lung ECM for tissue specificity. A study 
comparing decellularized lung and liver fragments found that these ECMs preferentially 
supported primary alveolar cells and hepatocytes, respectively [157]. Alveolar cells increased 
lung specific gene expression to a greater extent on lung ECM than liver ECM, while 
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heaptocytes effectively maintained morphology on liver ECM. An advantage of this study is that 
both tissues were decellularized with the same chemical treatments [157]. There have been 
numerous other studies that have focused on in vitro characterizations of biochemical 
composition [155-161] and/or mechanical properties [159, 160, 162] of a decellularized lung. 
These methods generally involve infusion of detergents through the vascular and/or conducting 
airways to remove cells and produce intact whole lung ECM. In addition to characterization, 
many of these studies investigated the effects of the lung ECM on cellular or physiologic 
function, in vitro or in vivo, respectively. Embryonic stem cell (ESC) derived lung progenitors 
seeded in intact lung form ciliated epithelium [163], and functional surfactant producing 
pneumocytes [159] in vitro. Furthermore, ESCs were affected by the local ECM environment 
and adopted lung cell phenotypes in appropriate anatomic locations (proximal vs. distal 
locations) [147]. Multipotential adult stem cells such as bone marrow derived mesenchymal stem 
cells (MSCs) were also maintained on lung ECM [160] and shown to respond to specific ECM 
components. MSCs preferentially migrated to regions of intact Type IV collagen and transiently 
expressed lung development markers, though they did not fully differentiate into pneumocytes.   
Finally, several studies have investigated homologous implantation of lung ECM 
recellularized with autologous cells in ex vivo organ engineering [88, 164, 165]. The goal of this 
approach is to repopulate the lung ECM with relevant cell lung populations in their proper 
anatomic location within the ECM. The cells and ECM are then preconditioned in vitro with 
physiologic mechanical and biochemical signals using a bioreactor to promote appropriate cell 
and, eventually, tissue function prior to implantation (Ott, Price 2010, Nichols, 2013). 
Recellularized lung ECM has been shown to facilitate gas exchange in vitro and in vivo where 
homologous implantation improved partial pressures of arterial oxygen and carbon dioxide 
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similar to lung transplantation. Pulmonary improvement can be maintained for several hours to 
one week before edema, inflammation, and fibrosis occurs and function declines. (Ott 2010, 
Song 2013) 
These reports generally support the use of tissue specific lung and liver ECM scaffolds. 
Such scaffolds maintain cell phenotype and function in vitro, and support homologous 
transplantation of recellularized ECM in vivo. These applications are greatly dependent on 
maintenance of the ECM structure as well as its composition for in vivo application and eventual 
ex vivo organ engineering.  
1.3.3.2 Skeletal muscle ECM 
Skeletal muscle ECM has shown mixed results for in vivo constructive remodeling. The 
first descriptions of decelluarized skeletal muscle were used for non-homologous implantation as 
a peripheral nerve graft [166]. The premise was to use the tubular basement membrane 
architecture as a conduit to guide regenerating nerve. The muscle supported some axonal growth 
through the graft, similar to allogeneic nerve grafting. Homologous muscle ECM implantation 
was first described in a series of studies using a deoxycholate detergent based protocol [92, 93, 
95, 98]. The resultant ECM maintained muscle ECM architecture and retained multiple growth 
factors, though these were not evaluated for full decellularization. The muscle ECM alone, or in 
combination with VEGF, was not effectively remodeled in muscle injury. Histologic evidence of 
myogenesis was induced, however, when scaffolds were pre-seeded and cultured with myoblasts 
prior to implantation. A similar observation was later found by Merritt et al., in which a 
combination of mesenchymal stem cells and muscle ECM was required for a constructive 
remodeling response [101, 102]. Combined implementation of support structures may improve 
the response however. Decellularization of both abdominal wall muscle tissue and its associated 
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fascia connective tissue layer showed that each had distinct effects on the immune response, 
angiogenesis, and myogenesis suggesting that the fascia layer may synergize with implanted 
muscle ECM [167]. Not all of these studies, however, rigorously evaluated how decellularization 
and residual cellular material may affect the response.  
Gillies et al. developed a novel approach to decellularization that did not use detergents, 
enzymes, or organic solvents, which have denaturing effects on ECM components [168-171]. 
DNA and intracellular protein removal was achieved using latrunculin B to induce actin 
polymerization and disrupt intracellular organization to allow solubilization and removal [168]. 
The host immune response to these non-detergent decellularized scaffolds has been extensively 
characterized and shown to promote anti-inflammatory macrophage and T-cell accumulation, 
though effects on myogenesis were not determined [172, 173]. Hydrogels composed of 
enzymatic degradation products of muscle ECM have also been evaluated [174, 175]. These 
pepsin digested muscle ECM scaffolds increased myoblast proliferation in vitro and markedly 
improved angiogenesis in vivo following ischemic injury, concomitant with recruitment of early 
myogenic cells.  
A number of studies have focused on evaluating the functional improvement of VML 
defect repair with skeletal muscle ECM scaffolds in vivo. Acellular muscle ECM implantation 
with subsequent remodeling in a VML injury model yielded some myogenesis within the defect 
[102, 176, 177]. However, force production was increased by approximately 50% compared to 
untreated defect controls. The authors concluded that the muscle ECM acted as a non-fibrotic 
bridge between the muscle stumps to allow continuous force transduction as the mechanism of 
improvement rather than de novo myogenesis [176]. A similar study using acellular muscle ECM 
found evidence that this force transduction through the ECM has a protective function on 
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adjacent muscle tissue preventing its degeneration and fibrosis in the absence of significant 
myogenesis [178]. Cell seeding the ECM prior to implantation improves functional recovery in a 
VML model, as seen with the increase in myogenesis, though cell delivery alone was not 
compared [101]. The role of ECM tissue specificity in these studies is difficult to ascertain since 
a non-muscle ECM was not compared, and the proposed mechanism of functional improvement 
are not dependent on site appropriate muscle formation.  
1.3.3.3 Cardiac ECM 
Cardiac muscle tissue has been decellularized from both whole intact hearts and heart 
fragments. Much like other whole organ decellularization methods, intact heart decellularization 
involves using the native vasculature to perfuse decellularization chemicals through the tissue. 
Typically, retrograde perfusion through the aorta is used due to the robustness of the aorta and 
left ventricle to withstand high pressures and flow [151, 179]. There have been several in vitro 
studies that have compared whole heart decellularization methods for cell removal efficacy, 
maintenance of structure, and retention of specific cardiac factors such as basement membrane 
proteins and glycosaminoglycans [180, 181] and biaxial mechanics [182]. Perfusion decell can 
also be effective through direct coronary perfusion in isolated regions of the myocardium [180, 
183]. Cardiac ECM prepared by left ventricle immersion decellularization maintained structure 
& mechanics, and supported MSC growth and myogenic differentiation in vitro, however these 
studies lacked comparisons to other ECM source tissues [184, 185]. These methods have also 
been optimized for decellularizing human cardiac tissue, which produced similar results to the 
porcine tissue [186]. Alternative forms of ECM have also been tested in MI repair. Powdered 
cardiac ECM injected into an MI model increased ejection fraction and decreased dilation. [187] 
Thin sheets of decellularized left ventricle were shown to be affected by the cell type with which 
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they are seeded.  Cardiac ECM seeded with fibroblasts contracted, though spontaneous beating 
was observed when the ECM was seeded with cardiomyocytes [188].  A composite cardiac left 
ventricle ECM/purified Type I collagen gel was able to direct ESC cardiomyogenesis in the 
absence of cardiac specific factors [189]. Human induced pluripotent stecm cells (iPS cells) 
seeded within intact mouse heart ECM differentiated more efficiently into cardiomyocytes which 
were able to spontaneously contract and generate measureable force [190]. Similar contractile 
results were obtained for intact rat heart ECM seeded with endothelial cells and cardiomyocytes 
[151].  Extensive investigation of cardiac ECM degradation products has shown significant 
effects on stem cell cardiomyogenic differentiation in vitro and functional improvements in vivo 
following MI. These hydrogel forming ECM degradation products not only impart bioactivity to 
reduce negative fibrotic remodeling outcomes, but can be delivered via minimally invasive 
means. ECM gel can be injected directly into multiple locations within infarcted tissue through 
femoral artery cannulation [120, 121, 191, 192].  
1.3.4 Studies that do not support a tissue specific hypothesis 
Most of the clinically utilized ECM scaffolds are used in non-homologous locations with varying 
degrees of success. Urinary bladder and/or small intestine derived ECM scaffolds have been 
utilized in lung [193], myocardial [110-119, 122] and skeletal muscle [91, 96, 97, 103-107] repair. 
Taken together, hese studies provide useful comparisons of the host response to the same non-
tissue specific ECM scaffolds (e.g. urinary bladder ECM) implanted in several different 
anatomic locations, and may elucidate general remodeling trends.  
There are few reports of the use of non-tissue specific lung ECM for lung applications. 
One example is application of urinary bladder ECM (UBM) for prevention of pulmonary 
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fibrosis. Particulate and enzymatically digested forms of UBM were intratracheally infused into 
the lung and shown to mitigate bleomycin induced pulmonary fibrosis [193]. Lung ECM was not 
evaluated in this model, but these results show that non-lung ECM can also provide beneficial 
effects to injured lung tissue in vivo. 
One of the most well characterized ECM materials is small intestinal submucosa (SIS) 
[194], which has been used in multiple clinical skeletal muscle applications such as rotator cuff 
repair and ventral hernia repair, as well as multiple pre-clinical studies to treat a multitude of 
tissues. SIS implantation in muscle locations have shown greatly increased myogenesis and 
functional improvements in musculotendinous junction and abdominal wall injury locations 
[105, 107], though this same material in a composite VML/periosteal injury was predisposed to 
promote bone and connective tissue formation rather than muscle [195]. This suggests that the 
effect of SIS may depend on implantation location and type of injury induced.  Urinary bladder 
derived ECM has a similar constructive remodeling response to SIS in muscle injury locations 
[99, 196, 197]. These scaffolds are degraded and remodeled with islands of skeletal muscle 
forming within the injury location. Studies have also shown that an anti-inflammatory 
macrophage phenotype is associated with improved remodeling and myogenesis in these models 
[196].  Stem cell seeded bladder ECM scaffolds markedly improved myogenesis and functional 
recovery in VML models, and was dependent on seeding density and preconditioning 
methodology prior to implantation. Acellular bladder ECM in this model improved function to a 
lesser extent, and with less myogenesis [198-200]. 
Non-cardiac specific urinary bladder and SIS ECM has also been investigated for cardiac 
repair applications in vivo, and have been shown to encourage remodeling and improve cardiac 
function [110-113, 115]. Cell seeding [122] or infusion with bioactive factors (e.g. exogenous 
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growth factors) prior to implantation further improves this functional recovery [116]. Like 
cardiac ECM, ECM degradation products prepared from small intestine ECM also encourages 
functional remodeling and protection from dilation and fibrosis [114, 201].  Most in vivo 
evaluations of cardiac ECM efficacy have been compared to synthetic materials such as Dacron, 
which are the clinical standard of care, rather than to other ECM devices [123, 179]. Both 
cardiac and non-tissue specific ECM have been more effective as cardiac patch materials 
compared to synthetics, though these studies do not establish tissue specific effects. Remlinger et 
al., however, did compare cardiac patches cut from whole heart ECM [202, 203] to patches 
composed of urinary bladder ECM for right ventricle outflow tract repair. Though both types of 
ECM promoted endothelialization and α-actinin positive cardiomyocyte formation, bladder ECM 
was more quickly and more effectively remodeled with new cardiomyocytes over the time 
course of this study than cardiac ECM [203]. However, the cardiac and urinary bladder ECM 
used in this study was very different in thickness and geometry prior to implantation, which may 
have affected remodeling. 
There is also a growing body of evidence supporting the use of these non-tissue specific 
ECM scaffolds for clinical repair of VML and cardiac defects. Urinary bladder ECM has been 
implanted in the repair of VML defects in quadriceps, tibialis anterior, and biceps muscles, 
which have resulted in greatly increased function [204]. This functional improvement was 
measured not only by force production, but also task completion, such as the ability to perform a 
range of different motions and activities necessary for normal ambulation [204] . Multiple case 
studies have reported the use of SIS ECM scaffolds for repairing congenital atrial septal defects 
(and other cardiac repair applications) in humans [117, 119, 205, 206]. There has been a low 
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incidence of adverse events, and follow up studies suggest good incorporation and remodeling. 
Tissue specific ECM scaffolds have not yet been clinically translated for these tissues, however.   
In both skeletal and cardiac muscle repair applications, non-homologous scaffolds are 
degraded and remodeled with reported increases in contractile function. Different studies have 
either shown advantages, disadvantages, or no difference in comparing tissue specific and non-
specific ECM. Each of these conclusions would lead to discordant interpretations. A tissue 
specific advantage would support the logic that the ECM of every tissue has been optimized 
during evolution to be the ideal scaffold for that tissue. However, the success of non-homologous 
ECM sources would imply that the compositional differences between different ECMs does not 
significantly affect tissue remodeling outcome in these applications, or that certain ECM sources 
universally provide necessary support to a wide array of tissues. 
1.3.5 Limitations in determining ECM tissue specificity 
Few studies provide well controlled comparisons between ECM scaffolds prepared from 
different tissues either in vitro, or more importantly, in vivo. Many of the aforementioned studies 
investigated a tissue specific ECM scaffold in isolation (or compared to synthetic materials), and 
thus characterized in vitro and in vivo responses without comparison to non-specific ECM. 
Though determinations of clinical feasibility and efficacy may be ascertained, this approach does 
not answer the question as to whether homologous utilization of a tissue specific scaffold confers 
an advantage in tissue remodeling to justify their use. Potential practical advantages of non-
homologous ECM scaffolds over homologous sources include a greater relative abundance or 
ease of preparation. Furthermore, those studies that did provide ECM comparisons are 
potentially confounded by differences in the decellularization method. These differences are to 
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be expected since each tissue possesses differing requirements to achieve adequate 
decellularization while still retaining ECM specific factors. However, these differences also 
affect the ability to make valid comparisons and so rigorous maintenance of similar processing 
methods are required. 
Additional research is required to determine if there is an advantage to utilizing a 
homologous scaffold in muscle injury, or whether only certain tissues are influenced by tissue 
specific effects. The goal of the proposed study is to determine the tissue specific effects of 
muscle derived ECM scaffold materials. To address the question of tissue specificity, ECM must 
be prepared using similar and controlled methods for all tissues. This study will compare ECMs 
prepared from cardiac muscle, skeletal muscle, and small intestine using a single 
decellularization protocol. In addition, small intestinal submucosa ECM will be prepared by a 
standard method of tissue decellularization to allow comparisons to previous studies that have 
used small intestinal ECM. 
 
1.4 HYPOTHESIS AND SPECIFIC AIMS 
1.4.1 Motivation and central hypothesis 
Tissue specific ECM scaffold utilization has been evaluated for multiple tissues and organs. 
Though certain tissues, such as lung and liver, appear to confer a clear advantage for 
homologous ECM implantation, skeletal and cardiac muscle tissues are less clear (see previous 
section).  The overall objective of the present work is to determine if a scaffold composed of 
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striated muscle ECM (cardiac or skeletal muscle) is superior for the treatment of muscle injury 
than scaffolds from non-muscle sources. The central hypothesis for this study is as follows: the 
skeletal muscle specific microenvironment in skeletal muscle ECM scaffolds facilitates a greater 
degree of functional restoration after muscle injury than non-muscle ECM scaffolds. The 
corollary to this hypothesis is that cardiac muscle ECM would also promote functional skeletal 
muscle remodeling relative to non-muscle ECM, but not to the extent of skeletal muscle ECM 
due to tissue specific differences between skeletal and cardiac muscle ECM. The following 
specific aims are designed to test this hypothesis in a systematic and controlled manner.  
1.4.2 Specific aim 1 
Isolate ECM from skeletal muscle tissue and characterize the structure and biochemical 
composition, and then to compare the structure and composition of skeletal muscle ECM 
scaffolds to ECM scaffolds derived from cardiac muscle and a non-muscle tissue source:  small 
intestinal submucosa prepared using either conventional methods or muscle ECM processing 
methods. 
1.4.3 Specific aim 2 
Determine the effect of ECM scaffold tissue source on muscle progenitor cell proliferation and 
differentiation in vitro using muscle and non-muscle ECM scaffold degradation products. 
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1.4.4 Specific aim 3 
Determine the in vivo remodeling characteristics of muscle and non-muscle ECM scaffolds in a 
model of murine volumetric skeletal muscle loss. 
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2.0  DEVELOPMENT AND CHARACTERIZATION OF A BIOLOGIC SCAFFOLD 
COMPOSED OF SKELETAL AND CARDIAC MUSCLE EXTRACELLULAR MATRIX1 
2.1 INTRODUCTION 
Biologic scaffold materials composed of extracellular matrix (ECM) are typically produced by 
decellularization of mammalian tissues such as urinary bladder, dermis, or small intestine [74] 
and have been shown to facilitate the functional reconstruction of several tissue types [207, 208] 
including the lower urinary tract [77, 209], heart and vascular structures [111, 117], esophagus 
[79, 96], and musculoskeletal tissues [97, 103, 105, 107], among others. The mechanisms by 
which constructive remodeling occurs include the recruitment of multipotential stem and 
progenitor cells to the site of scaffold placement [210, 211], promotion of a favorable M2 
macrophage phenotype at the host tissue/bioscaffold interface [197], regional angiogenesis [106], 
and mitogenesis [211, 212]. These tissue derived biologic scaffolds are frequently used in non-
homologous anatomic sites, but recent studies have suggested that biologic scaffolds derived 
from site specific homologous tissues such as liver and lung may be better suited for constructive 
tissue remodeling than non-site specific tissue sources [85, 88, 147, 149, 150, 152, 213].  
1This work has been adapted from the following published manuscript:  
Wolf MT, Daly KA, Reing JE, Badylak SF. Biologic scaffold composed of skeletal muscle extracellular matrix. 
Biomaterials. 2012;33(10): 2916-25. http://dx.doi.org/10.1016/j.biomaterials.2011.12.055 
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Muscle tissues, including cardiac, skeletal, and smooth muscle, respond favorably when 
biologic scaffolds are used for their reconstruction following injury [105, 107]. To date, there 
have been several attempts to isolate and process skeletal muscle ECM (M-ECM) [92, 93, 95, 
98, 102, 168, 175, 214]. Most of these attempts have involved the decellularization of intact 
rodent muscles or the extraction of rodent muscle ECM proteins, with varying degrees of 
success.   DeQuach et al. [175] did show that proteins extracted from a decellularized porcine 
muscle matrix retain bioactivity.  None of these studies have provided a detailed characterization 
of the intact M-ECM scaffold derived from a large animal tissue source, nor have any of these 
studies applied stringent decellularization criteria in the development of the decellularization 
process. The objectives of the present study were to 1) determine a method for decellularization 
of skeletal muscle and characterize the structure and composition of the resulting ECM, and 2) to 
compare the in-vitro bioactivity and in-vivo remodeling properties of skeletal muscle ECM vs. 
non-muscle ECM, specifically SIS, in a rodent model of abdominal wall muscle repair. 
Following this initial assessment of in vitro and in vivo compatibility, M-ECM was prepared 
from porcine skeletal muscle to compare its composition to porcine cardiac ECM (C-ECM), 
small intestinal submucosa prepared using the M-ECM protocol (SIS-M) and porcine SIS using 
the standard protocol. These comparison groups are provided in Table 2.  
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 Table 2. Summary of each ECM group’s tissue source and the decellularization method. 
 
2.2 METHODS 
2.2.1 Overview of experimental design 
The present aim was encompassed two primary objectives. The first was to develop a consistent 
methodology of decellularizing skeletal muscle. This was achieved by decellularizing canine 
skeletal muscle by enzymatic and chemical methods. The resulting M-ECM was then assessed 
for structure and cytocompatibility: the effect on cell attachment and metabolism in vitro, and the 
in vivo remodeling characteristics in a rat abdominal wall defect model. ECM composed of 
porcine small intestinal submucosa (SIS) was used for comparison purposes. The second 
objective was to apply this decellularization procedure to porcine skeletal muscle, cardiac 
muscle, and small intestine, and then to characterize the composition of the resultant scaffolds. 
All animal experiments were conducted in accordance to University of Pittsburgh Institutional 
Animal Care and Use Committee (IACUC) regulations and guidelines. 
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2.2.2 Skeletal muscle decellularization protocol 
Whole quadriceps and hamstring muscle groups were isolated from mongrel dogs and frozen at -
80°C immediately following sacrifice. While frozen, entire muscle groups were then sliced into 
2.25 mm thick sheets transverse to the alignment of muscle fibers.  The muscle slices were then 
thawed and trimmed of all macroscopic vasculature, fat, and connective tissues, rinsed in 
deionized water for 1 hour and lyophilized. Muscle tissue slices were then decellularized in 
batches weighing approximately 18-20 g (dry wt.) 
The lyophilized muscle was decellularized following the protocol summarized in Table 3. 
Briefly, the muscle was subjected to lipid extraction by placement in a 2:1 (v/v) solution of 
chloroform/methanol (Fisher, Waltham, MA) for 2 hours under a constant stir rate [215]. The 
muscle was rehydrated using a graded series of ethanol and then exposed to a series of enzymatic 
and chemical treatments to remove cellular materials in a spinner flask at a stir rate of 70RPM. 
These treatments consisted of: 0.2% Trypsin/0.2% EDTA for 2 hours (at 37 ºC and pH = 7.6), 
2% sodium deoxycholate for 5 hours, 2% sodium deoxycholate for 14-16 hours, 1% Triton-X 
100 for 1 hour, and finally 0.1% (w/v) peracetic acid/4% (v/v) ethanol for 2 hours followed by 
extensive rinsing. The muscle tissue was washed with deionized water and 2X phosphate 
buffered saline (PBS) between each step. The M-ECM scaffolds were lyophilized for storage. 
Scaffolds used for tissue culture or in vivo implantion were terminally sterilized with ethylene 
oxide (16 hour cycle at 50°C in a Series 3plus EOGas Sterilizer, Anderson Sterilizers, Inc. Haw 
River, NC).  
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Table 3. Summary of the steps in the decellularization of skeletal muscle tissue including the chemical 
treatment and time of exposure. 
 
2.2.3 Conventional small intestine decellularization and muscle decellularization method 
Porcine small intestine (jejunum) was obtained from 6 month old pigs from the local abbatoir 
and prepared as previously described [216]. In brief, the majority of the mucosa and the entire  
serosa, and muscularis externa layers of the intestine were mechanically delaminated from the 
intestine. Approximately 80 g (wet wt.) of the remaining submucosa, muscularis mucosa and 
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stratum compactum layers were washed with water and treated with 1.6 L of 0.1% (w/v) 
peracetic acid/4% (v/v) ethanol for 1 hour. SIS was then rinsed extensively, lyophilized, and 
sterilized with ethylene oxide. 
SIS-M was prepared by exposing 5 cm x 5 cm sheets of the isolated submucosa, 
muscularis mucosa and stratum compactum layers to the muscle decellularization protocol. 
Intestine sheets were lyophilized and exposed to the same treatments as Table 2.   
2.2.4 Verification of muscle decellularization 
Decellularization was defined as fulfilling the following criteria for DNA content: having less 
than 50 ng dsDNA/mg ECM dry weight, having all residual DNA fragments be less than 200 
base pair in size, and lacking visible nuclei after histologic staining with 4',6-diamidino-2-
phenylindole (DAPI). [74]  Immediately after processing, M-ECM samples (n = 7) were fixed in 
10% neutral buffered formalin. Samples were then embedded in paraffin, surface sectioned, and 
then stained with H&E and DAPI for detection of nuclei multispectrally at 200X magnification. 
(Nuance multispectral imaging, CRi, Cambridge, MA) Additional non-fixed samples were used 
to quantify the amount of double stranded DNA using the PicoGreen assay (Invitrogen, 
Carlsbad, CA). DNA was extracted from powdered M-ECM by digesting in 0.1 mg/ml 
proteinase K (Sigma, St. Louis, MO) at 50ºC for 24 hours. Samples were then purified with two 
phenol/chloroform/isoamyl alcohol (25:24:1 v/v) extractions. After ethanol precipitation and 
drying, the DNA was resuspended in 1ml TE buffer (pH = 8.0) then quantified using the 
PicoGreen assay according to the manufacturer’s instructions. The size of the extracted DNA 
fragments was determined after separation by 2% agarose gel electrophoresis. 
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2.2.5 Scanning electron microscopy 
Scanning electron micrographs were taken to examine the surface topology of M-ECM and 
native muscle tissue. Prior to final lyophilization, samples were fixed in cold 2.5% (v/v) 
glutaraldeyde (Electron Microscopy Sciences, Hatfield, PA) in PBS for at least 24 hours, 
followed by three washes in PBS.  Lipid fixation was performed in 1% (w/v) osmium tetroxide 
(Electron Microscopy Sciences) for 1 hour followed by three washes in PBS.  Fixed samples 
were then dehydrated using a graded series of alcohol (30, 50, 70, 90, 100%) for 15 minutes 
each, followed by 15 minutes in hexamethylenediamine (Fisher) and subsequent air drying. The 
dried samples were sputter coated with a 3.5nm layer of gold/palladium alloy using a Sputter 
Coater 108 Auto (Cressington Scientific Instruments, Watford, UK) and imaged with a JEOL 
JSM6330f scanning electron microscope (JEOL, Peabody, MA) at 25X, 500X, 1000X, and 
10,000X magnifications. 
2.2.6 Cell culture and metabolism on M-ECM scaffolds 
C2C12 mouse myoblast, human perivascular stem cell, NIH 3T3 mouse fibroblast, and human 
microvascular endothelial cell (HMEC) lines  were cultured on the surface of M-ECM scaffolds 
and the abluminal side of SIS  to evaluate in vitro cell compatibility. The perivascular stem cells 
were isolated from fetal skeletal muscle (as described by Crisan et al. [217]), and passage 8-12 
was utilized for all experiments.  The HMEC, C2C12, and NIH 3T3 cell lines were obtained 
from ATCC (Manassas, VA).  C2C12 and NIH 3T3 cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 
(Hyclone) and 100U/ml penicillin/100μg/ml streptomycin (Invitrogen). HMECs were cultured in 
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MDCB131 Medium (Invitrogen), supplemented with 10% FBS and 100U/ml 
penicillin/100μg/ml streptomycin. Perivascular stem cells were cultured in DMEM supplemented 
with 20% FBS and 100U/ml penicillin/100μg/ml streptomycin. C2C12 cells were also cultured 
in low serum conditions to induce myotube formation, which consisted of DMEM supplemented 
with 2% horse serum and 100U/ml penicillin/100μg/ml streptomycin. 
 C2C12 cells, perivascular stem cells, NIH 3T3 cells, and HMEC cells were seeded on the 
surface of lyophilized sheets of M-ECM at a density of 500,000 cells/cm2 for 7 days, with media 
changes after the 1st and 4th days. C2C12 cells were grown in both high serum and low serum 
differentiation conditions. The cell seeded scaffolds were then fixed in formalin, cut into 5 μm 
cross sections,  and stained with H&E. These were imaged at 200X magnification and evaluated 
for cell morphology characteristics. Perivascular stem cell seeded scaffolds were also fixed with 
formalin and labeled with Alexa Fluor-546 conjugated phalloidin (Invitrogen) for actin and 
DAPI for nuclei. The scaffold surface was then imaged with a confocal microscope. (Leica DMI 
4000B, Leica Microsystems, Buffalo Grove, IL) 
Lyophilized M-ECM and SIS sheets (n = 6-12) from 2 different scaffold preparations 
were cut into 8mm disks using a biopsy hole punch, placed into a 96-well plate, and anchored to 
the bottom of the wells with silicone rings. The disks were sterilized with ethylene oxide (16 
hour cycle at 50°C in a Series 3plus EOGas Sterilizer) and seeded in triplicate with C2C12 
myoblasts or perivascular stem cells at a density of 4,000 cells/well in 200 μl of media. Cells 
were also seeded in wells with only the plastic anchor ring as controls (n = 3-6). Cells were 
cultured for 1, 3, and 5 days in standard media, and at each timepoint, cell metabolism was 
assessed using the alamar blue assay (Invitrogen). Alamar Blue reagent was added to each well 
for 6 hours, then transferred to a separate plate and read fluorescently (ex:560, em:590). A non-
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seeded scaffold background control was subtracted from each reading. All values were 
normalized to a standard curve of 1,000-20,000 cells/well adding Alamar Blue 4 hours after 
seeding and measuring after 6 hours of incubation in the Alamar Blue reagent. 
2.2.7 Acute evaluation of an M-ECM scaffold in a rat abdominal wall defect model 
The in vivo remodeling characteristics of M-ECM and SIS scaffolds were determined in a partial 
thickness abdominal wall defect model in the rat. [127] A 1x1 cm partial thickness defect was 
created in the ventrolateral abdominal wall of female Sprague-Dawley rats by removing the 
external and internal oblique muscles (both are skeletal muscle) while leaving the transversalis 
muscle and the peritoneum intact.  The defect was repaired with a 1x1 cm sheet of M-ECM or 
SIS sutured at the 4 corners of the defect with 4-0 Prolene sutures (Ethicon Inc., Somerville, NJ), 
or left untreated with no implanted ECM as a defect only control. The skin incision was then 
closed with absorbable 4-0 Vicryl sutures (Ethicon) and the rats were allowed to recover 
normally. Rats were sacrificed 14 and 35 days post-implantation (n = 4 per group per time point), 
and the repaired defects were excised and fixed with formalin. Explants were then embedded in 
paraffin, sectioned, and stained with Masson’s Trichrome stain or immunolabeled for fast and 
slow myosin heavy chain (MHC) to evaluate myogenesis as previously described [105, 218]. 
Slides were deparaffinized followed by epitope retrieval in 0.1 mM EDTA at 95-100 ºC for 25 
minutes and then 0.1% Trypsin/0.1% Calcium Chloride (w/v) at 37 ºC for 10 minutes. 
Endogenous peroxidase activity was quenched by incubation in a 0.3% (v/v) hydrogen peroxide 
solution in TBS for 10 minutes at room temperature. Sections were then blocked with 2% normal 
horse serum/1% BSA in TBS (Vector) for 30 minutes at room temperature and then labeled with 
mouse anti-slow myosin heavy chain (1:1000, M8421, Sigma) for 40 minutes at room 
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temperature. Sections were then rinsed in TBS and incubated in a biotinylated goat anti-mouse 
IgG secondary antibody (1:200, Vector) diluted in blocking solution for 1 hour at room 
temperature. Sections were washed as before and incubated in the Vectastain ABC reagent 
(Vector) for 30 minutes at room temperature and then exposed to a diaminobenzadine substrate 
(ImmPact DAB, Vector) until appropriate staining developed. Sections were then incubated in 
blocking solution for 10 minutes followed by incubation in alkaline phosphatase conjugated 
mouse anti-fast myosin heavy chain (1:200, A4335, Sigma) diluted in blocking solution for 1 
hour. After rinsing, color was developed by staining with red alkaline phosphatase (Vector) until 
appropriate staining developed. Slides were then counterstained with hematoxylin, dehydrated, 
and cover slipped. 
2.2.8 Protein extraction and growth factor quantification 
Soluble proteins were extracted from different preparations of M-ECM , C-ECM, SIS-M, and 
SIS (n = 3 each), and native muscle tissues (n = 2) and analyzed for growth factor content. 
Soluble proteins were extracted from 300 mg of powdered ECM or tissue in 7ml of a urea-
heparin buffer (2M urea, 50mM Tris, 5 mg/ml heparin, 10mM N-ethylmaleimide, 5mM 
benzamidine, and 1mM phenylmethylsulfonyl fluoride at pH = 7.4). Samples in urea-heparin 
buffer were gently agitated for 20-24 hours at 4ºC, after which they were centrifuged for 30 
minutes at 3,000g and the supernatant collected. The remaining pellet was resuspended in freshly 
prepared urea-heparin buffer and the extraction process repeated. Each extract was then dialyzed 
against 80-100x volume of deionized water using 3500MWCO Slide-A-Lyzer dialysis cassettes 
(Pierce, Rockford, IL) for 24 hours, with water changes after 4 and 8 hours. The recovered 
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extracts were analyzed for total protein recovered using the BCA protein assay (Pierce) and 
frozen at -80°C until further use. 
 The isolated protein extracts were quantified for vascular endothelial growth factor 
(VEGF) and basic fibroblast growth factor (bFGF) with human ELISAs (R&D systems, 
Minneapolis, MN) following the manufacturer’s instructions. Canine, porcine, and human bFGF 
and VEGF show a high level of sequence homology and extractions from native porcine tissue 
were found to be reactive with the human ELISA kits used. 
2.2.9 ECM staining and immunolabeling 
M-ECM, C-ECM, SIS-M, SIS, and native muscle tissue were fixed in formalin, embedded in 
paraffin, and then cut into 5 μm sections. Standard histologic stains were performed using 
Herovici’s Polychrome (staining for collagen Types I & III) and Movat’s Pentachrome (staining 
for elastin, collagen, and GAGs). Immunolabeling studies were also conducted for the presence 
of basement membrane proteins laminin, type IV collagen, and fibronectin.  
For immunolabeling, slides were deparaffinized followed by epitope retrieval in 10mM 
citrate buffer (pH = 6.0) at 95ºC for 15 minutes. Endogenous peroxidase activity was quenched 
by incubation in a 3% (v/v) hydrogen peroxide/methanol solution for 30 minutes at room 
temperature. Non-specific antibody binding was blocked with 2% normal goat serum in PBS 
(Vector, Burlingame, CA) for 1 hour at room temperature. Tissues were then labeled with 
primary antibodies overnight at 4 ºC. Antibodies were raised in rabbit against human laminin 
(1:50, L9393, Sigma), type IV collagen (1:100, T59106R, Meridian Life Science Inc., Saco, 
ME), and fibronectin (1:300, F3648, Sigma) and were diluted in the blocking solution. Sections 
were then rinsed in PBS and incubated in a biotinylated goat anti-rabbit IgG secondary antibody 
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(1:100, Vector) diluted in blocking solution for 2 hours at room temperature. Sections were 
rinsed as before and incubated in the Vectastain ABC reagent (Vector) for 30 minutes at room 
temperature and then exposed to a diaminobenzadine substrate (ImmPact DAB, Vector) until 
appropriate staining developed. Staining was stopped by rinsing sections in deionized water 
followed by counterstaining with hematoxylin. Antibody isotype controls were used in the place 
of the primary antibody to determine the presence of non-specific staining. 
2.2.10 Sulfated glycosaminoglycan quantification 
Sulfated glycosaminoglycan (GAG) content in different preparations of M-ECM, C-ECM, SIS-
M, and SIS (n = 3) was determined using the Blyscan Sulfated Glycosaminoglycan Assay Kit 
(Biocolor Life Sciences, Carrickfergus, UK). For each sample, 10 mg/ml of powdered ECM was 
enzymatically digested with pepsin for 48 hours at room temperature. The digested scaffold was 
then assayed following the manufacturer’s instructions. 
2.2.11 Statistical analysis 
All statistical analysis was performed using MATLAB software (MathWorks, Natick, MA). 
Metabolic activity differences were determined for both C2C12 myoblast and perivascular stem 
cell seeded scaffolds. Each substrate at every time point was analyzed using a two-way analysis 
of variance (ANOVA) with a Tukey post-hoc test and with a significance level of p < 0.05. All 
values are given as the mean ± standard deviation. 
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2.3 RESULTS 
2.3.1 Verification of decellularization 
The amount and size of residual DNA content after decellularization for each preparation of M-
ECM prepared was quantified and is presented in Figure 2. Histologic analysis of M-ECM 
(Figure 2A & C) showed no evidence of intact nuclear material on H&E or DAPI as compared to 
native muscle (Figure 2B & D). After decellularization, there was 7.42 + 1.67 ng DNA/mg dry 
weight compared to the 1549 + 489 ng DNA/mg dry weight found in native muscle tissue 
(Figure 2E). There were no clearly visible bands of DNA after separation on a 2% agarose gel, 
while native muscle showed a range of DNA fragments (Figure 2F). These values met previously 
described criteria of decellularization [74]. 
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 Figure 2. Residual DNA content of M-ECM scaffolds after decellularization for each batch 
tested in the study (n=7) compared to native muscle (n=2). Histologic appearance after H&E 
staining of (A) M-ECM and (B) native muscle tissue, and after DAPI staining of (C) M-ECM 
and (D) native muscle, bar represents 100 μm. The DAPI stained M-ECM is overexposed and 
imaged multispectrally displaying scaffold autofluorescence as grey and nuclei as blue. (E) 
Results of the PicoGreen analysis for double stranded DNA extracted per mg dry weight of 
scaffolds ± SD. (F) Extracted DNA from several batches of M-ECM separated via 2% agarose 
gel electrophoresis and compared with native muscle and a 100 bp ladder.  
2.3.2 Scanning electron microscopy 
The surface topology of M-ECM scaffolds was compared to native muscle tissue using SEM and 
is presented in Figure 3. M-ECM had an uneven surface composed of compact structures in a net 
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like pattern (Figure 3A-D). Higher magnification revealed that these structures consisted of long 
compact fibrils or bundles of fibrils with a banding pattern suggestive of collagen (Figure 3D, 
arrows). No myofiber cellular remnants were seen. In contrast, native muscle showed clear 
tubular myofiber boundaries with densely packed microfribrillar elements within each cell 
(Figure 3E-F). 
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 Figure 3. SEM images of M-ECM and native muscle tissue. M-ECM was imaged at (A) 25X, 
(B) 500X, (C) 1,000X, and (D) 10,000X magnifications and compared to native muscle cross 
sections at (E) 500X and (F) 5,000X. Long fibrils with a collagen-like banding pattern were 
observed in the M-ECM scaffold. 
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2.3.3 Cell culture and metabolism on M-ECM scaffolds 
Cell attachment, survival, and morphology was assessed using histologic methods for M-ECM 
and SIS scaffolds seeded with the following cell lines for 7 days in culture: C2C12 myoblasts 
(Figure 4A & B), human perivascular stem cells (Figure 4C-E), NIH 3T3 fibroblasts, HMEC 
endothelial cells, and differentiated C2C12 myotubes (Figure 5). Histologic cross sections 
showed a confluent layer of cells on the surface that possessed a normal, healthy morphology for 
all cell types on both M-ECM and SIS. Normal cell morphology was further confirmed for 
perivascular stem cells by staining and imaging the surface with phalloidin for actin (Figure 4E) 
showing spread cell morphology forming a confluent monolayer. C2C12 differentiation was 
supported on both M-ECM (Figure 5E & F) with the presence of elongated multinucleate 
myotubes upon histologic examination. 
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 Figure 4. In vitro cell compatibility histology of (A,C) C2C12 myoblasts and (B,D,E) 
perivascular stem cells cultured for 7 days on the surface of M-ECM (A,B,E) or SIS (C,D). 
Representative images of (A-D) H&E cross sections and (E) fluorescent imaging labeling with 
phalloidin for actin (red) or DAPI for nuclei (blue). Scale bar represents 100 μm.  
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 Figure 5. In vitro cell compatibility histology of (A-B) NIH 3T3 fibroblasts, (C-D)  human 
microvascular endothelial cells, and differentiated C2C12 myoblasts (E-F) after 7 days of culture 
on (A,C,E) M-ECM or (B,D,F) SIS sheets. H&E stained. Scale bar represents 100 μm.  
 
The proliferation of C2C12 myoblasts (Figure 6A) and perivascular stem cells (Figure 
6B) seeded on M-ECM and SIS scaffolds or seeded in empty wells (TC) was estimated from the 
Alamar Blue assay and all differences defined as p < 0.05.  C2C12 metabolic activity was greater 
on seeded TC than SIS from day 1 onward, and greater than M-ECM from day 3 on. The 
metabolic activity of cells seeded on M-ECM did not change over the time course of the study, 
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but SIS and TC seeded cells promoted an increase from day 1 at days 5 and 3, respectively. In 
contrast, perivascular stem cells seeded on TC did not show alterations in metabolic activity over 
the time course of the study. Both M-ECM and SIS seeded scaffolds showed an increase in cell 
metabolism between days 1 and 5. 
 
Figure 6. Alamar Blue assay for cellular metabolism of (A) C2C12 myoblasts  and (B) 
perivascular stem cells seeded on the surface of M-ECM sheets, SIS sheets, or tissue culture 
plastic (TC) controls for 1, 3, and 5 days. Results normalized to standard curve of cells assayed 
on TC 4 hours after seeding. Significance defined as p < 0.05 and * denotes a difference from 
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day 1 within a group, # denotes a difference from SIS within a timepoint, and † denotes a 
difference from M-ECM within a timepoint. 
2.3.4 Acute evaluation of an M-ECM scaffold in a rat abdominal wall defect model 
M-ECM and SIS sheets were implanted in a partial thickness abdominal wall defect for 14 and 
35 days and evaluated by histologic methods. At 14 days, both M-ECM and SIS scaffolds 
showed a robust mononuclear cell response with a dense accumulation of cells around the 
implants (Figure 7A-D). Compared to M-ECM, the SIS scaffold displayed a greater extent of 
degradation as shown by a highly fragmented scaffold appearance at 14 days (Figure 7B & D, 
asterisks).  There were occasional multinucleate cells in direct contact with the M-ECM scaffold 
(Figure 8B, arrowheads) that was absent in the SIS group. Both implants showed angiogenesis 
around the scaffolds (Figure 7B & D). By 35 days, the mononuclear cell response had largely 
dissipated in both scaffolds and there was evidence of myogenesis within a more organized 
collagenous connective tissue. (Figure 7E-H)  
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 Figure 7. In vivo response to implanted (A-B,E-F,I-J) M-ECM  and (C-D,G-H,K-L) SIS after 
(A-D) 14  and (E-L) 35 days. Low magnification (100X) images (A,C,E,G,I,K) are presented 
with black boxes denoting regions of interest for high magnification (400X) images presented 
directly to the right (B,D,F,H,J,L). Sections were stained with (A-H) Masson’s Trichrome or (I-
L) immunolabeled for fast (red) and slow (brown) myosin heavy chain (MHC). There are 
obvious scaffold remnants at 14 days for both scaffolds (asterisks), and multinucleate cells 
around M-ECM scaffold regions (arrowheads). Scale bars represent 100 μm. 
 
For M-ECM, there were still scattered regions in which the scaffold had not completely 
degraded, with collagenous bands of scaffold visible on histologic examination (Figure 8A, 
asterisks) with associated multinucleate cells (Figure 8A, arrowheads). The SIS scaffold was 
more completely degraded, with the infrequent exception of scattered small fragments (Figure 
8B, asterisks) surrounded by a dense accumulation of mononuclear cells. Islands of small 
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diameter muscle fibers staining positive for slow or fast myosin heavy chain were occasionally 
found in the defect at the interface with the subjacent transversalis fascia. (Figure 7I-L)  A 
greater proportion of the muscle stained positive for fast myosin than slow, consistent with the 
staining pattern in adjacent native muscle. There was no apparent difference in the amount or 
phenotype of new muscle observed between M-ECM and SIS scaffolds at the 35 day time point. 
 
 
Figure 8. Areas of incomplete (A) M-ECM and (B) SIS scaffold degradation after 35 days in 
vivo after Masson’s Tricrome staining. Scattered M-ECM scaffold remnants (asterisks) are 
apparent in some regions of the defect, but such regions are smaller and more diffuse for SIS. M-
ECM scaffold remnants are also associated with multinucleate cells (arrowheads). Scale bar 
represents 100 μm. 
 
The unrepaired defect only control group at 35 days showed only a thin layer of 
collagenous connective tissue within the defect area, and little evidence of continued remodeling. 
(Figure 9A & B) There was a dispersed spindle shaped cell population and no observed 
myogenic cells. 
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 Figure 9. In vivo remodeling response to an unrepaired partial thickness abdominal wall defect 
after 35 days. Images were acquired at low magnification (A, 100X) with a black box denoting a 
region of interest for a high magnification (B, 400X) image . Scale bars represent 100 μm. 
 
2.3.5 Application of the skeletal muscle decellularization method to cardiac and small 
intestine tissues 
Following the initial development and cytocompatibility of the chemical skeletal muscle 
decellularization protocol (see previous sections), this method was applied to sheets of porcine 
psoas major skeletal muscle, cardiac left ventricle, and small intestinal submucosa as shown in 
Figure 10A-C. Each tissue was decellularized, resulting in thin white sheets of ECM for use in 
subsequent analyses (Figure 10D-F).  
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 Figure 10. Native porcine psoas major skeletal muscle, left ventricle, and small intestine sheets 
(A-C) were decellularized using the muscle protocol to yield acellular ECM scaffolds (D-F). 
2.3.6 Protein extraction and growth factor quantification 
Soluble proteins remaining in M-ECM, C-ECM, SIS-M, SIS, and native tissues were extracted 
using urea-heparin extraction buffer and then were quantified using the BCA protein assay. The 
amount of protein extracted from M-ECM was 2.30 + 0.57 mg protein/g dry weight for M-ECM, 
which was two orders of magnitude less than the 203.03 + 30.74 extracted from native muscle 
tissue and one order of magnitude less than the 23.04 + 2.52 extracted from SIS. Similar 
quantities of protein were obtained from C-ECM and SIS-M extracts. 
 There was no detectable VEGF extracted (Figure 11A) from  any of the decellularized 
tissues, though native muscle contained 31.91 + 12.93 ng VEGF/g dry weight. Total amounts of 
bFGF are presented in Figure 11B. M-ECM, C-ECM, and SIS-M retained bFGF, though in lower 
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amounts than SIS. Total bFGF content was found to be between 3.10-10.15 ± 2.34 ng bFGF/g 
dry weight in M-ECM, C-ECM, and SIS-M, which was less than the 75.22 + 19.57 found in SIS 
and the 39.70 + 8.28 ng bFGF/g dry weight found in native muscle or 125.4 ng/g in native small 
intestine.  
 
 
Figure 11. Biochemical growth factor analysis of M-ECM, C-ECM, SIS-M, and SIS compared 
to their native tissues. (A) Vascular endothelial growth factor (VEGF) and (B) basic fibroblast 
growth factor (bFGF) were quantified by ELISA from urea heparin extracted protein.   
 
2.3.7 ECM staining and immunolabeling 
ECM scaffolds and native muscle was stained with Herovici’s Polychrome and Movat’s 
Pentachrome stains as shown in Figure 12 and Figure 13, respectively. Herovici’s staining of 
native muscle showed a distribution of thick type I collagen in the perimysium (pink/purple) and 
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type III collagen staining (blue) around individual muscle fibers consistent with previous studies 
(Figure 12A). [219, 220] Herovici’s staining of M-ECM, C-ECM, SIS-M, and SIS showed thick 
Type I collagen bundles and dispersed strands of Type III collagen. (Figure 12B-E) Thicker 
bundles of both Type I and III collagen were observed in SIS scaffolds (Figure 12E). Movat’s 
pentachrome showed the presence of elastin (black, arrows Figure 13). Elastin was primarily 
associated with blood vessels in native tissue, and in was localized to long strands that are 
possible remnants of blood vessels in each ECM. Staining patterns were similar for M-ECM, C-
ECM, and SIS-M, though SIS had more dense protein as well as non-vessel associated elastin 
staining (Figure 13E).  
 
Figure 12. Herovici’s Polychrome staining of native muscle (A), M-ECM (B), C-ECM (C), SIS-
M (D), and SIS (E). Type I collagen fibers stain as pink/purple and Type III collagen stains blue. 
Scale bar represents 100 μm.  
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 Figure 13. Movat’s Pentachrome staining of native muscle (A), M-ECM (B), C-ECM (C), SIS-
M (D), and SIS (E). Dense protein regions stain red and elastin stains black and is highlighted by 
arrows. Scale bar represents 100 μm.  
 
ECM scaffolds and native muscle tissue showed evidence of basement membrane 
proteins fibronectin (Figure 14), Type IV Collagen (Figure 15), and laminin (Figure 16). In 
native muscle, there was a clear localization of type IV collagen and laminin to the basement 
membrane surrounding muscle fibers (Figure 15A and Figure 16A). Fibronectin was found on 
basement membranes of native muscle as well as the interstitial connective tissue (Figure 14A). 
Each ECM showed abundant fibronectin staining (Figure 14), and isolated regions of Type IV 
collagen (Figure 15, arrows), with the most widespread staining visible in SIS. There were only 
occasional regions of laminin staining in all ECM groups (Figure 16, arrows). Antibody isotype 
controls verified the lack of non-specific staining (data not shown). 
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 Figure 14. Fibronectin immunolabeling of native muscle (A), M-ECM (B), C-ECM (C), SIS-M 
(D), and SIS (E). Positive staining is indicated by brown ECM staining. Scale bar represents 100 
μm.  
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 Figure 15. Type IV collagen immunolableing of native muscle (A), M-ECM (B), C-ECM (C), 
SIS-M (D), and SIS (E). Positive staining is indicated by brown ECM staining and is highlighted 
with arrows. Scale bar represents 100 μm.  
 
57 
 Figure 16. Laminin immunolableing of native muscle (A), M-ECM (B), C-ECM (C), SIS-M 
(D), and SIS (E). Positive staining is indicated by brown ECM staining and is highlighted with 
arrows. Scale bar represents 100 μm.  
 
2.3.8 Sulfated glycosaminoglycan quantification 
The results of the GAG assay are summarized in Figure 17. M-ECM contained 0.88 ± 0.8 μg/mg 
dry weight of sulfated GAGs after decellularization, which was similar to C-ECM and SIS-M 
with 0.24 ± 0.03 and 0.54 ± 0.22 μg/mg, respectively. SIS had the greatest amount of GAGs with 
4.5 ± 0.36 μg/mg dry weight. 
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 Figure 17. Sulfated GAG content of each ECM scaffold following enzymatic digestion. (*) 
indicates a difference from all other groups (p < 0.05).  
2.4 DISCUSSION 
A method for the preparation of skeletal muscle ECM scaffolds from a large animal tissue source 
is described in the present study. The M-ECM scaffold was shown to be thoroughly 
decellularized by established criteria while simultaneously preserving many of the components 
found in the native ECM. The bioactivity of the scaffold was evaluated and shown to affect the 
proliferative potential of muscle progenitor cells in vitro as well as the induction of a 
constructive remodeling response in vivo.   Although differences were identified in the structure 
and composition of the ECM scaffolds prepared from skeletal muscle and small intestinal 
submucosa, no differences were present in their respective effects upon the remodeling of 
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skeletal muscle in a rodent model. This method was then applied to cardiac (left ventricle) and 
small intestinal submucosa tissue, where there was similar retention of bioactive factors in each 
tissue. 
The method of preparation of an ECM scaffold can have profound effects upon the 
composition, ultrastructure, and subsequent host response to the scaffold following implantation. 
Skeletal muscle ECM scaffolds have been prepared and evaluated for the purpose of in vivo 
skeletal muscle reconstruction and several different decellularization approaches have been 
described. Merritt et al. provided a detailed assessment of the in vivo host response to acellular 
skeletal muscle and observed myogenesis at the scaffold/tissue interface, but found functional 
recovery only when mesenchymal stem cells were pre-seeded on the scaffold [101, 102]. This 
study utilized a relatively harsh decellularization protocol compared to methods described in the 
present study. Such harsh methods are effective at removing cellular material but also effectively 
denature matrix components [170, 171]. Other studies have reported the use of decellularized 
muscle tissue with less harsh decellularization protocols; however, quantification of 
decellularization was not attempted. While most visible nuclear material can be removed 
following decellularization attempts, cell remnants remain within the matrix, which can 
adversely affect in vivo remodeling. Consequently, less than ideal remodeling responses occur in 
vivo with the exception of those scaffolds preseeded with myogenic cells.[92, 93, 95, 98].  
Although most clinical applications of ECM scaffolds have involved a non-homologous 
implantation site, there have been recent studies which suggest an advantage for the use of site 
specific ECM [84, 85, 88, 147, 149, 150, 152, 153]. The concept of tissue specificity in ECM 
scaffolds is predicated upon the concept that there is a unique structure and composition within 
each tissue, and even within different regions of individual tissues. The ECM of tissues and 
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organs provides a microenvironmental niche for resident cells that promotes and maintains site 
appropriate phenotype and function [221]. This niche environment is the sum of both structural 
and biochemical milieu that includes collagens, glycosaminoglycans, proteoglycans, and bound 
growth factors, among others that may influence myogenesis and the remodeling response. [46]  
The M-ECM characterized in the present study maintains several of the factors found in 
native muscle tissue including basement membrane proteins and GAGs. Growth factors can be 
sequestered within the ECM, and FGF was shown in the present study to survive the 
decellularization process. Although assays used in the present study do not determine biologic 
activity, previous studies have shown that growth factors within decellularized tissues can 
stimulate cells in culture [222] [223, 224]. The differences in composition between M-ECM and 
SIS in the present study are most likely explained by not only the different tissue sources (muscle 
vs. small intestine), but also by the different decellularization techniques that were used. SIS is a 
thin material prepared primarily by mechanical methods from the parent small intestine tissue 
and a brief exposure to peracetic acid. M-ECM on the other hand uses enzymatic and detergent 
chemical methods that have different effects upon the matrix. This is supported by the similar 
values obtained for SIS-M following the same muscle decellularization protocol.  
In addition to the retention of components found in the native ECM, M-ECM was shown 
to be cell compatible for a number of cell types in vitro as evaluated using histologic methods 
and with the Alamar Blue assay. C2C12 cells seeded on M-ECM and SIS were similar in their 
metabolic profile over the time course of the study, which was less than in non-ECM covered 
wells. Perivascular stem cells seeded on M-ECM and SIS, however, showed greater growth over 
time compared to non-ECM covered cells. These effects may have been due to the presence of 
ECM specific attachment proteins, or soluble growth factors that may have eluted from the 
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scaffold during culture. It should be noted that the Alamar Blue assay is a metabolic assay, which 
is not directly correlated to cell number in all circumstances. 
The determinants of success for biologic scaffold remodeling in vivo are not fully 
understood, but empirical observations have proven informative.  SIS that is prepared without 
chemical crosslinking has been shown to promote a constructive remodeling response, 
myogenesis, and partial restoration of function [105, 107]. Thoroughness of decellularization, as 
attained in the present study, avoids a pro-inflammatory response whereas ineffective 
decellularization is associated with a robust inflammatory response [129]. ECM scaffold 
degradation is another determinant of remodeling outcome. Degradation products of ECM 
scaffolds have been shown to have chemotactic and mitogenic effects on stem cells in vitro and 
in vivo, [211, 212] and inhibition of scaffold degradation is associated with less desirable 
outcomes [106, 107]. M-ECM, like SIS and other previously evaluated scaffolds, invokes a 
strong cellular response at early timepoints, which dissipates over time in a partial thickness 
abdominal wall defect model. M-ECM showed a morphologically different cell population, 
specifically, multinucleate cells, in direct contact with the scaffold at 14 days. Multinucleate cells 
were not seen in the tissue response to the SIS-ECM scaffold.  M-ECM did appear to degrade 
more slowly than SIS, with some intact M-ECM scaffold fragments still visible at 35 days. There 
was extensive remodeling in areas where the M-ECM had degraded, with small islands of 
myosin heavy chain expressing muscle cells in the defect area in a very similar pattern to SIS at 
this time point. In contrast, the unrepaired defect only control, exhibited very little remodeling 
and no myogenesis confirming the positive influence of M-ECM and SIS scaffolds on the host 
response.  Despite the numerous differences in the structure, composition, and early host 
responses between M-ECM and SIS, the remodeling characteristics and myogenesis at 35 days 
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were indistinguishable.   It is possible that there will be additional divergence in the remodeling 
outcome at later time points when remodeling is complete.  
The results of this aim show that a M-ECM scaffold can be prepared from a large animal 
source using an enzymatic and chemical processing method. The M-ECM conforms with 
established decellularization criteria while preserving factors found in native muscle ECM that 
may be beneficial to the host remodeling response. The M-ECM exerts biologic effects on 
myogenic cells in vitro and promotes positive remodeling characteristics in a rodent muscle 
defect model.  However, when compared to the nonhomologous SIS there was no detectable 
advantage in using a tissue specific M-ECM scaffold, despite differences in the structure and 
composition of the two bioscaffold materials. ECM composition was maintained to a similar 
extent in resultant C-ECM and SIS-M ECM scaffolds, showing that this method is applicable to 
other tissues and that they alter the ECM to similar extents. Conventional SIS retained greater 
quantities of growth factors and GAGs, which is likely due to the stronger detergents and greater 
exposure time in the muscle decellularization protocol compared to SIS. Though compositional 
similarities were observed between tissues, relatively broad detection methods were utilized. 
Laminin and Type IV collagen, for example, encompass multiple isoforms that have divergent, 
tissue specific functions [69, 70, 225-228]. Likewise, there are multiple types of sulfated 
glycosaminoglycans (e.g. heparan sulfate and chondroitin sulfate) [229, 230] as well many 
possible post-translational glycosylation protein modifications.  The total Type IV collagen, 
laminin, and glycosaminoglycan content evaluated in the present study was non-specific, and 
likely spanned different isoforms in different ratios for each tissue. Future studies investigating 
the roles of these specific isoforms are required to determine whether different isoforms directly 
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exert differences in the cell response to these scaffolds, and may act as a mechanism of ECM 
tissue specificity.   
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3.0  THE EFFECT OF SKELETAL AND CARDIAC MUSCLE EXTRACELLULAR 
MATRIX  DEGRADATION PRODUCTS ON SKELETAL AND CARDIAC MUSCLE 
PERIVASCULAR STEM CELLS 
3.1 INTRODUCTION 
Extracellular matrix (ECM) from decellularized tissues has been used as an inductive biologic 
scaffold for tissue reconstruction in several clinical applications such as rotator cuff repair [231, 
232], ventral hernia repair [91, 97, 233-235], breast reconstruction [236], and heart valve 
replacement [237]. The decellularization process removes the majority of the tissues cell 
components, resulting in an implantable acellular scaffold composed of the native ECM [74, 
130]. The utility of ECM scaffolds derives from their ability to remodel into site appropriate host 
tissue after implantation in a site of injury, a process termed constructive remodeling [73]. 
During this process, ECM scaffolds are rapidly infiltrated by mononuclear cells, fully degraded 
[71, 238], and replaced with a mixture of loose connective tissue and site specific functional cells 
(e.g. myogenic progenitors/myofibers in skeletal muscle) [105, 107]. This is in contrast with 
default wound healing, which proceeds through the development of a provisional scaffold and 
eventual dense fibrous scar tissue deposition [239]. ECM scaffolds have been prepared from 
numerous tissues including small intestine, urinary bladder [200, 240], dermis [235, 241], 
pericardium [109, 242], and recently, skeletal [108, 168, 178] and cardiac muscle [179, 186, 202] 
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tissues. The ECM from each of these source tissues has a composition and microstructure that is 
optimal for its resident cells, and it is from these differences that the concept of tissue specific 
ECM scaffolds has arisen. A tissue specific ECM hypothesis postulates that an ECM scaffold 
provides optimal biologic signals and/or microenvironment to cells derived from the same tissue.  
The mechanisms of ECM constructive remodeling are only partially understood, several 
processes have been implicated in the response, and many of these are dependent on ECM 
degradation and subsequent release of matricryptic molecules [71, 238, 243]. These molecules 
are small fragments of the native ECM possessing new biologic activity that is not present in the 
intact parent ECM molecule [243-245]. Such matricyptic molecules have been described in 
biological contexts such as angiogenesis, cancer invasion, homeostasis, wound healing, and 
recently, during ECM scaffold degradation and remodeling [210, 243, 245]. ECM scaffold 
degradation products have shown chemotactic and mitogenic effects on stem cells in vitro [211, 
246] and in vivo [210, 245, 246], and are a potential mediator of ECM remodeling.  
Perivascular stem cells (PVSCs) belong to a multipotential, vessel associated stem cell 
population capable of osteogenic, adipogeic, chondrogenic, and myogenic differentiation in vitro 
and in vivo [217, 247]. PVSCs have been isolated and characterized from several fetal and adult 
tissues, which includes skeletal muscle [217, 247], placenta, bone marrow, pancreas, cardiac 
muscle (unpublished data), liver [248], and adipose tissue [217]. Their wide anatomical 
distribution has suggested a ubiquitous role in wound healing and regeneration of vascularized 
tissues.  Furthermore, PVSCs isolated from different tissues have been proposed to possess 
different characteristics, such as differentiation capacity and surface marker expression, 
indicating tissue specific PVSC differences (unpublished data). This provides an opportunity to 
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examine a similar stem cell population derived from both skeletal and cardiac muscle anatomic 
locations, rather than skeletal muscle satellite cells for which there is no cardiac analogue.  
 The objective of the present study was to determine whether ECM scaffolds possess 
tissue specific inductive effects on PVSCs from the same donor and/or different tissue origin.  
Specifically, the effects of ECM degradation products derived from skeletal muscle, cardiac 
muscle, and non-muscle tissue were characterized on human skeletal and cardiac muscle derived 
PVSCs in vitro.     
3.2 METHODS 
3.2.1 Overview of experimental design 
ECM scaffold degradation products were prepared in vitro from decellularized skeletal 
muscle (M-ECM), cardiac muscle (C-ECM), and small intestinal submucosa (SIS-M) using 
identical  decellularization protocols. Small intestinal submucosa prepared via conventional 
methods (SIS) was also included to determine effects of different decellularization methods upon 
the response to the same ECM. PVSCs were exposed to ECM degradation products in vitro and 
ECM effects upon proliferation and differentiation were characterized. 
3.2.2 Preparation of ECM degradation products 
Psoas major skeletal muscle, cardiac left ventricle free wall, and small intestine tissues were 
obtained from market weight pigs (approx. 100 kg) and decellularized using a modified version 
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of a previously established protocol for skeletal muscle ECM. Skeletal and cardiac muscle were 
sliced into 2.2 mm cross sectional sheets (transverse to the longitudinal axis) using a rotating 
blade. Small intestinal submucosa sheets were prepared by isolating the stratum compactum, 
muscularis mucosa, and submucosal from the other layers via mechanical delamination. All 
tissues were then frozen and lyophilized. The dried tissue sheets were delipidized by stirring in a 
chloroform/methanol solution (2:1 v/v, Sigma) for 30 minutes, followed by a graded series of 
ethanol (100, 100, 95, 70, and 50%) for 30 minutes each and then several water washes. Tissues 
were then frozen until further processing in a spinner flask at 70 RPM. Tissues were 
enzymatically processed with 0.2% Trypsin/0.2% EDTA (Sigma) at 37 °C for 2 hours, and then 
placed in alternating 20 minute hypotonic/hypertonic washes of deionized water and 2X PBS, 
respectively. Detergent treatment with 2% sodium deoxycholate (Sigma) for 5 hours was 
performed to solubilize cell components, followed by another pair of hypotonic/hypertonic 
washes and a fresh change of 2% sodium deoxycholate for 16 hours. A 1% Triton X-100 (pH=8, 
Sigma) solution was used to remove residual deoxycholate for 1 hour, which was followed by 2 
washes in deionized water. Final decellularization was achieved after exposure to 0.1% peracetic 
acid/4% ethanol for 2 hours and residual chemicals removed via extensive washing: 2 washes 
with PBS and  2 washes in deionized water for 30 minutes each, 1X PBS for 16 hours, and 4 
washes in deionized water. The resultant M-ECM, C-ECM, and SIS-M ECM sheets were frozen 
and lyophilized. 
Lyophilized ECM was comminuted into a particulate form and partially enzymatically 
digested with 1 mg/ml pepsin (Sigma) in 0.01 M HCl for 48 hours at room temperature with 
agitation to final ECM concentration of 10 mg/ml (dry wt/volume). The resulting degradation 
products were frozen until addition to cell culture media. ECM digests were neutralized with 
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10X PBS (1/9 digest volume) and NaOH (1/10 digest volume), and diluted to desired 
concentrations with the appropriate media for each assay. Type I rat tail collagen (BD 
Biosciences) was neutralized according to manufacturer’s instructions. Control buffers consisted 
of  pepsin buffer (1 mg/ml pepsin in 0.01 M HCl without ECM) and pepsin-free buffer (0.01 M 
HCl only), which were neutralized and diluted in the same way as the ECM digests. 
3.2.3 Skeletal and cardiac perivascular stem cell (PVSC) isolation and culture conditions 
Skeletal and cardiac muscle derived perivascular stem cells were isolated from human fetal 
skeletal and cardiac muscle tissue, respectively, from the same donor as previously described by 
Crisan et al. [217]. Human fetal tissues (17-23 weeks of development) were obtained following 
voluntary or therapeutic pregnancy interruptions performed at Magee-Womens Hospital, in 
compliance with the University of Pittsburgh Institutional Review Board protocol 0506176, and 
after obtaining informed consent from the patient for use of the tissues. Developmental age was 
estimated by medical history and measurement of foot length.  
For skeletal muscle, cells were dissociated by cutting the fresh tissue into small pieces 
and incubating with collagenases I, II, and IV at a concentration of 1 mg/ml for 1 hour at 37 °C 
with gentle agitation. Remaining tissue fragments were then fully dissociated by mechanical 
separation with forceps, and incubated for an additional 10 minutes in collagenases with gentle 
agitation. For cardiac tissue, cells were dissociated by cutting the fresh tissue into very small 
pieces, mincing mechanically, and incubating in the dissociation solution containing 
collagenases I, II, and IV at a concentration of 1 mg/ml for 15-20 min at 37 °C with gentle 
agitation. Dissociated tissues were neutralized with an equal amount of DMEM (Dulbeco’s 
modified Eagle’s medium, Gibco) containing 10% fetal bovine serum (FBS, Invitrogen) and 1% 
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penicillin-streptomycin (P/S, Invitrogen). After centrifugation, pellets were washed, resuspended 
in PBS, and sequentially passed through 100- and 70-μm cell strainers to obtain single cell 
suspension. Cells were then incubated in erythrocyte lysis buffer (155 mM NH4Cl, 10mM 
KHCO3, 0,1mM EDTA) for 10 min at room temperature. After centrifugation, cells were 
resuspended in PBS and passed through a 70-μm cell strainer if debris is observed. 
 Fluorescent activated cell sorting (FACS) was performed to purify PVSCs from the 
skeletal and cardiac muscle tissues using a FACSAria flow cytometer (BD). CD56+ 
myogenic/natural killer cell (anti-CD56-PE-Cy7, Serotec, 1:100), CD45+ hematopoietic cell 
(anti-CD45-APC-Cy7, Santa Cruz Biotechnologies, 1:100), CD34+ endothelial cell (anti-CD34-
APC, Becton-Dickinson, 1:100), and c-kit+ cardiac stem cell (anti-CD117-PE, Serotec, 1:100) 
populations were gated out of the single cell suspension, and PVSCs were positively selected for 
expression of pericyte markers CD146 (anti-CD146-FITC, Serotec, 1:100). Sorted PVSCs were 
plated at a maximum density of 2x104 cells/cm and cultured for 1 passage on gelatin-coated 
plates in endothelial cell growth medium (EGM2 complete, Lonza). PVSCs were subsequently 
expanded in proliferation medium (20% FBS, 1% penicillin/streptomycin, DMEM), which also 
maintained an undifferentiated phenotype, and all cells were used between passages 9-12. 
3.2.4 PVSC myogenic differentiation 
The effect of skeletal and cardiac muscle ECM degradation products on skeletal and cardiac 
PVSCs was determined by immunolabeling for myogenic and cardiomyogenic phenotypic 
markers after differentiation culture conditions. Skeletal and cardiac muscle PVSCs each have 
different culture requirements to induce differentiation as shown in Figure 18. 
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 Figure 18. In vitro culture conditions for skeletal and cardiac muscle PVSC myogenic 
differentiation. PVSCs were plated, grown to confluency, changed to myogenic pre-conditioning 
media (with and without ECM degradation products) and finally changed to low serum fusion 
media (with and without ECM degradation products). Cardiac PVSCs were grown to confluence, 
pulsed with 5-azacytidine, and cultured in high serum cardiac differentiation media (10% FBS).  
 
 Skeletal muscle PVSCs (Figure 18A) were plated in 24 well plates at a density of 5,000 
cells/cm2 and grown to 95% confluence in proliferation media (typically 3-4 days). Proliferation 
media was then replaced with myogenic pre-conditioning media consisting of 10% FBS, 10% 
horse serum (Gibco), 1% chick embryo extract (Accurate Chemical), and 1% 
penicillin/streptomycin in DMEM for 7 days, and supplemented with neutralized ECM 
degradation products at a concentration of 100 μg ECM/ml, 100 μg type I rat tail collagen/ml 
(BD), or buffer controls (pepsin buffer or pepsin-free buffer). Full differentiation was induced by 
replacing the myogenic media with fusion media (1% FBS, 1% horse serum, 0.1% chick embryo 
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extract, 1% penicillin/streptomycin in DMEM) for 10 days. One half media changes were 
performed every 2 days for each media condition. 
 Cardiac muscle PVSCs were differentiated towards a cardiomyogenic lineage using MSC 
differentiation conditions (BFigure 18). Cardiac PVSCs were plated in 24 well plates at the same 
initial density as skeletal muscle PVSCs (5,000 cells/cm2) and grown to 95% confluency in 
proliferation media (typically 4-5 days). Proliferation media was then replaced with 10% FBS in 
DMEM supplemented with 10 nM 5-azacytidine (Sigma) for 3 days followed by differentiation 
media (10% FBS, 1% penicillin/streptomycin in DMEM) for an additional 7 days, and 
supplemented with neutralized ECM degradation products at a concentration of 100 μg ECM/ml, 
or buffer controls. One half media changes were performed every 2 days during differentiation 
culture. 
 Following differentiation, PVSCs were fixed within the well plates with 2% 
paraformeldahyde for 20 minutes at room temperature, and immunolabeled for skeletal and 
cardiac muscle differentiation markers. A subset of cells was fixed 1 day after initial plating to 
ensure PVSC phenotype expressing CD146 and NG2 surface markers. After fixation, cells were 
washed with PBS and simultaneously permeablized and non-specific protein binding blocked 
(1% bovine serum albumin, 2% horse serum, 0.1% Triton X-100, and 0.1% Tween 20 in PBS) 
for 1 hour. The blocking solution was decanted and immediately incubated with primary 
antibody diluted in blocking solution overnight at 4 °C. The following primary mouse 
monoclonal antibodies were used: anti-GATA4 (1:200, clone G-4, sc-25310, Santa Cruz 
Biotechnology), anti-MyoD (1:100, clone 5.8A, MA1-41017, Thermo Fisher), anti-fast myosin 
heavy chain (MHC) (1:250, clone My-32, M1570, Sigma-Aldrich), anti-cardiac MHC (1:200, 
clone BA-G5, ab50967, Abcam), and anti-sarcomeric MHC (1:250, clone MF-20, 
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Developmental Studies Hybridoma Bank). Cells were washed with PBS and incubated with 
secondary antibody diluted in blocking solution (1:250, goat anti-mouse Alexa Fluor 488 
conjugate, Invitrogen)  for 1 hour, followed by washing and nuclear counter staining with 4',6-
diamidino-2-phenylindole (DAPI, Invitrogen). Each labeling condition was performed in 
triplicate wells for each of the three batches of ECM degradation products.   
Individual wells were imaged via epifluorescence using an inverted microscope configuration 
(Zeiss, AxioVision), and at least 3 representative images were acquired from each well. Skeletal 
muscle specific differentiation was determined by expression of MyoD and fast MHC, and 
cardiac muscle differentiation determined by expression of GATA4 and cardiac MHC. PVSC 
fusion characteristics were quantified from the frequency and morphology of sarcomeric myosin 
heavy chain expressing cells. Since fusion was a rare event (less than 1% of cells) that typically 
localized to a few locations within the well, images were acquired to evaluate the maturity of 
fused cells. These fusion characteristics include: (1) the number of MHC expressing cells, (2) the 
total number of fused PVSCs defined as MHC expressing cells containing more than one nuclei, 
(3) the total length of MHC expressing cells, (4) the area of MHC expressing cells, (5) and the 
fusion index defined as the ratio of nuclei within fused MHC expressing cells to total nuclei per 
field. 
3.2.5 BrdU incorporation assay for PVSC proliferation 
The effect of ECM degradation product conditioned media upon PVSC proliferation was 
determined by 5-Bromo-2´-Deoxyuridine (BrdU) incorporation in serum free conditions as well 
as serum conditions identical to those used during the differentiation experiments (Figure 19). 
The serum free assay (Figure 19A) began by plating PVSCs a 96 well plate at cell densities of 
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1,000 and 2,000 cells per well for skeletal muscle and cardiac muscle derived PVSCs, 
respectively. These cell seeding densities were determined empirically and differ due to the 
differing growth characteristics of skeletal and cardiac muscle PVSCs. Media was added to all 
empty wells to mitigate the effects of media evaporation in wells nearer the edge of the plate. 
Cells were allowed to attach and acclimate in growth media within the wells for 32 hours, which 
was then replaced with low serum media (0.5% FBS, 1% penicillin/streptomycin, DMEM) for 18 
hours. Cells were then treated with serum free media supplemented with 10 μM BrdU (Sigma) 
ECM (25, 50, or 100 μg ECM/ml), Type I collagen (25, 50, or 100 μg collagen/ml), pepsin and 
pepsin-free buffer (with dilution factors equivalent to those used for ECM conditions), or a high 
serum positive control media (5% FBS, 1% penicillin/streptomycin, DMEM). Each ECM batch 
was tested in quadruplicate wells. PVSCs were incubated in each treatment condition for 18 
hours and fixed with 95% methanol for 15 minutes at room temperature.   
 The high serum assay (Figure 19B) was conducted in culture conditions that recapitulated 
those in the differentiation assay. Skeletal and cardiac muscle PVSCs were both seeded within 
96 well plates at a density of 5,000 cells per well and allowed to attach and acclimate for 24 
hours in growth media. Cells were then treated with high serum media supplemented with 100 
μg ECM/ml, 100 μg collagen/ml, or pepsin and pepsin-free buffer controls. Myogenic 
preconditioning media was used for skeletal muscle PVSCs and differentiation media was the 
basal media for cardiac muscle PVSCs for the treatment duration. PVSCs were incubated for a 
total of 24 hours in each treatment condition, with the addition of concentrated BrdU (final 
concentration of 10 μM in each well) during the final 4 hours of treatment followed by fixation. 
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 Figure 19. Summary of in vitro culture conditions for PVSC BrdU incorporation assays in serum 
free (A) and high serum (B) media with or without ECM supplementation. PVSCs in the low 
serum assay were serum starved for 18 hours and pulsed with ECM and BrdU for the following 
18 hours. The high serum assay was conducted in high serum corresponding to the 
differentiation conditions in the respective skeletal and cardiac muscle differentiation assays.  
  
BrdU incorporation was quantified via immunofluorscent labeling and imaging of PVSCs 
within wells. Non specific protein binding was blocked with 1% bovine serum albumin in PBS 
for 1 hour at room temperature. Plates were then decanted and immediately incubated with 
mouse anti-BrdU primary antibody diluted in blocking solution (1:1000, clone G3G4, 
Developmental Studies Hybridoma Bank) overnight at 4 °C. Plates were washed and incubated 
with secondary antibody diluted in blocking solution (1:250, goat anti-mouse Alexa Fluor 488 
conjugate, Invitrogen)  for 1 hour, and nuclei labeled with DAPI (Invitrogen). Mosaic images 
(composed of 35 individual 100X magnification images) that encompassed entire wells were 
acquired automatically using AxioVision software (AxioVision v4.7.1, Zeiss). The number of 
cells incorporating BrdU and the total number of nuclei within each well were quantified from 
the mosaic images automatically using a custom algorithm (Appendix A) developed with ImageJ 
software (National Institute of Health, Bethesda, MD). In brief, the original images were split 
into blue and green color channels and processed to remove background fluorescence, enhance 
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contrast, and count the number of nuclei and BrdU staining cells based on size exclusion (Figure 
20). Only nuclei colocalized with BrdU staining were counted as BrdU positive cells. The 
percentage of total nuclei with BrdU incorporation was determined for each treatment and 
expressed as a percent change from the pepsin-free buffer condition. 
 
Figure 20. Example outputs of a PVSC seeded well stained and analyzed for BrdU incorporation 
using a custom ImageJ algorithm. The original mosaic image (A) was split into blue and green 
color channels, processed, and size gated to count the number of nuclei (B) and BrdU staining 
nuclei (C) from the ImageJ output mask images. Only blue/green colocalized masks were 
counted as positive BrdU incorporation (D).  
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3.2.6 Statistical analysis 
All values are reported as the mean ± standard deviation. Statistical differences between ECM 
treatments in the serum free proliferation assay were determined with a two-way analysis of 
variance (ANOVA) for the factors ECM treatment and concentration with a post-hoc Tukey’s 
test. Statistical significance for the high serum proliferation assay was determined using a one-
way ANOVA with post-hoc Tukey’s test. Significant differences were defined as a p-value < 
0.05.  
3.3 RESULTS 
3.3.1 PVSC myogenic differentiation 
Skeletal and cardiac muscle PVSCs were differentiated at high confluence with or without ECM 
degradation products, and both PVSC cultures were affected by the addition of ECM. The initial 
PVSC phenotype was confirmed as co-expressing the pericyte surface markers CD146 and NG2 
(Figure 21A-B), while also not expressing skeletal or cardiac muscle differentiation markers 
such as GATA4, MyoD, and sarcomeric MHC (Figure 21C-E). During the course of culture with 
ECM and Type I collagen only, PVSCs assumed an elongated and contractile phenotype. Highly 
confluent cell sheets would contract and begin to detach from the edges of the well inward and 
care was necessary to avoid full detachment during media changes or staining. Cell contraction 
and elongation was also evident from the shape of the nuclei, which also presented with an 
elongated aspect ratio. This effect was most pronounced in M-ECM, C-ECM, and SIS treatment 
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groups, though it was also observed to a lesser extent in SIS-M and Type I collagen treated 
wells.  
 
Figure 21. The initial skeletal and cardiac muscle PVSC phenotype prior to myogenic 
differentiation conditions. PVSCs co-expressed pericyte markers CD146 (A) and NG2 (B), while 
not expressing MyoD (C), GATA4 (D), or sarcomeric MHC (E). Scale bar represents 100 μm.  
 
 Under these differentiation conditions, PVSCs expressed a combination of skeletal and 
cardiac muscle differentiation markers that are not present in non-differentiating culture 
conditions. Skeletal muscle PVSCs, even in the absence of ECM, highly expressed the cardiac 
associated marker GATA4 in approximately 90% of cells. In contrast, the early myogenic 
commitment marker MyoD was only very rarely expressed in less than 0.01% of cells. ECM 
treatment and Type I collagen did not affect these expression characteristics.  
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Figure 22. Skeletal muscle PVSC expression of GATA4 and MyoD following differentiation 
without ECM. Nearly all cells expressed GATA4 (A-B, green), while there was only extremely 
rare expression of MyoD (C-D, green). These results were also typical following each ECM 
treatment. Nuclei were labeled with DAPI (blue). Scale bars represent 100 μm.  
 
Mature muscle contractile markers were affected by the addition of ECM degradation 
products. ECM free conditions expressed a mixed phenotype of cardiac and fast skeletal muscle 
myosin heavy chain, and rarely, cell fusion. ECM treatment induced low levels of cardiac MHC 
expression in approximately 50% of cells, which was not found in pepsin control treated wells 
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(Figure 23). This expression pattern was found in mononuclear and fused PVSCs and was 
similar for each ECM treatment.  
 
Figure 23. Cardiac MHC expression (green) in skeletal muscle PVSCs following differentiation 
in pepsin control buffer (A), ECM degradation products (M-ECM (B), C-ECM (C), SIS (D), and 
SIS-M (E)), or purified Type I collagen (F). Nuclei were labeled with DAPI (blue). Scale bar 
represents 100 μm.  
 
Fast skeletal muscle MHC was not as prevalent as cardiac MHC, though was also 
increased by ECM treatment (Figure 24). The majority of cells expressing fast MHC were fused 
rather than mononuclear cells.  
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 Figure 24. Fast skeletal muscle MHC expression (green) in skeletal muscle PVSCs following 
differentiation in pepsin control buffer (A), ECM degradation products (M-ECM (B), C-ECM 
(C), SIS (D), and SIS-M (E)), or purified Type I collagen (F). Nuclei stained with DAPI (blue). 
Scale bar represents 100 μm.  
 
Fused cells expressing sarcomeric MHC without ECM treatment (buffer or Type I 
collagen) had smaller cell areas and fewer nuclei per cell, and were less numerous than with 
ECM treatment (Figure 25). Though rare, ECM treatment increased fusion, which would occur 
in localized regions in the well plate. SIS increased the total number of fused cells (MHC 
positive cells containing more than 1 nuclei) relative to pepsin buffer and SIS-M.  However, only 
M-ECM and C-ECM treatment resulted in an increase in the number of nuclei per fused cell. No 
treatment affected the total area of MHC expressing cells.  
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 Figure 25. Skeletal muscle PVSC fusion analysis using sarcomeric MHC expression after 
exposure to pepsin buffer, M-ECM, C-ECM, SIS-M, or SIS degradation products, or Type I 
collagen. Fused cells (A, green) were analyzed for total number of fused MHC+ cells (B), total 
nuclei within MHC+ cells (C), and total MHC+ cell area (D). Statistically significant differences 
were determined by two-way ANOVA (p  < 0.05) and denoted with (*). Scale bar represents 100 
μm.  
 
Unlike skeletal muscle PVSCs, cardiac PVSC differentiation was not affected by the 
addition of ECM degradation products. Cardiac PVSCs expressed very high levels of GATA4 
similar to skeletal muscle PVSCs, though they were not competent for cell fusion or expression 
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of any other differentiation markers. Cell contractility and elongation was observed after ECM 
treatment, muscle contractile markers were not apparent (Figure 26). 
 
Figure 26. Cardiac PVSCs did not express mature myogenic markers. Scale bar represents 
100 μm.  
3.3.2 BrdU incorporation assay for PVSC proliferation 
ECM degradation products were added to skeletal and cardiac muscle PVSCs in serum free and 
high serum conditions and expressed as the % change in BrdU incorporation with respect to the 
pepsin free buffer condition. ECM degradation products in serum free media (Figure 27) had a 
minimal effect on skeletal muscle PVSC proliferation, and only C-ECM induced a slight 
decrease in BrdU incorporation compared to pepsin buffer, with a non-dose dependent decrease 
of 24-50% compared to pepsin free buffer. SIS degradation products increased proliferation in 
cardiac PVSCs (6-32% increase) compared to pepsin buffer (17% decrease-15% increase) and 
Type I collagen (8% decrease-21% increase). 
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 Figure 27. BrdU incorporation in skeletal muscle (A) and cardiac muscle (B) PVSCs with ECM 
exposure in low serum conditions. Each treatment was applied at 100, 50, and 25 μg/ml 
concentrations. Values were normalized to untreated cells without ECM or pepsin buffer. 
Statistically significant differences were determined by two-way ANOVA (p  < 0.05) and 
denoted with (*). Bars over groups of concentrations indicate that there was a difference due to 
treatment group, but not due to a concentration or interaction effect.  
 
In high serum conditions, all ECM treatments and Type I collagen reduced BrdU 
incorporation in both skeletal (Figure 28A) and cardiac muscle PVSCs (Figure 28B). Skeletal 
muscle PVSCs exhibited a 5% increase in BrdU incorporation for pepsin buffer controls 
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compared to a 32-42% decrease for various ECM treatments, which were not statistically 
different from each other. Cardiac PVSCs were also reduced from a 0% change for pepsin buffer 
to a 32-52% decrease for ECM treatments, though no ECM treatments were statistically 
different. 
 
 
Figure 28. BrdU incorporation in skeletal muscle (A) and cardiac muscle (B) PVSCs with ECM 
exposure in high serum conditions. Statistically significant differences were determined by one-
way ANOVA (p  < 0.05) and denoted with (*). Each treatment resulted in a significant decrease 
in BrdU incorporation compared to pepsin buffer control.  
 
3.4  DISCUSSION 
The present study showed that PVSCs derived from skeletal and cardiac muscle vary in their in 
vitro myogenic differention potential and their responsiveness to muscle and non-muscle ECM 
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scaffold degradation products. Skeletal muscle PVSCs differentiated towards a myogenic 
phenotype coexpressing both skeletal and cardiac muscle markers, and with increased fusion 
following ECM treatment with M-ECM, C-ECM, and SIS. Cardiac PVSCs, however, did not 
effectively express contractile markers or fuse in culture, and ECM exposure did not change this 
response. Relatively small changes in proliferation were induced by ECM degradation products 
for PVSC types in low serum conditions in which C-ECM decreased skeletal muscle PVSC 
proliferation while SIS increased cardiac PVSC proliferation. Both ECM treatment and Type I 
collagen in high serum conditions decreased proliferation for both skeletal and cardiac muscle 
PVSCs. 
ECM scaffolds are prepared by tissue decellullarization, and have been shown to be 
effective in promoting a constructive remodeling response in musculotendinous tissue [105], 
cardiac tissue [203], liver [85], esophagus [82], and other anatomic locations. ECM remodeling 
is likely a complex process that involves multiple wound healing processes and cell types. 
Immune modulation, cell recruitment, and stem cell activation and proliferation are all processes 
that have been implicated during ECM remodeling, and it is probable that these are intricately 
linked [196]. PVSCs are a recently described cell source that reside in multiple vascularized 
tissues [217, 247, 248], and express mesenchymal stem cell markers. These cells are normally 
associated in a perivascular location surrounding small blood vessels, but migrate away from this 
niche following ECM implantation [217] where they may participate in remodeling. Though 
PVSC activation is correlated with myogenesis (unpublished data, submitted), their precise role 
has not been defined and may include direct transdifferentiation or release of paracrine factors.  
Multiple studies have shown that rapid ECM degradation is a necessary event for 
constructive remodeling and that the prevention of degradation by chemically crosslinking ECM 
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scaffolds results in pro-inflammatory immune activation and fibrotic encapsulation of the device 
[128, 233, 249]. This observation has prompted a number of studies that have evaluated 
degradation products in vitro and in vivo as a potential mediator of remodeling. Native ECM 
degradation products have been shown to influence cell behavior such as proliferation and 
migration in biologic contexts such as tumor invasion and angiogenesis [243, 244]. These 
degradation products are a complex mixture of small, biologically active ECM fragments known 
as matricryptic molecules that possess activity that is not present in the parent ECM molecule. In 
vitro prepared ECM degradation products resulting from pepsin digestion have been shown to be 
an effective model system of the effect of ECM degradation. Pepsin digested urinary bladder 
ECM (UBM-ECM) has been shown to increase stem cell proliferation and migration in vitro 
[211], and to recruit multipotential stem cells in after digit amputation in vivo [245, 246]. Other 
studies have shown proliferative and differentiation effects on myogenic and neuronal stem cells 
in vitro and in vivo when injected in these injured tissues [174, 175, 250].    
ECM degradation products represent a rich milieu of factors whose composition is 
dependent on the original composition of the ECM scaffold. These include cell adhesion 
proteins, glycosaminoglycans, and other proteoglycans that release multiple unique small ECM 
fragments upon degradation. Since the intact ECM scaffold composition varies by tissue, each 
will then result in a unique profile of degradation products. These degradation products have not 
yet been fully characterized, however, size distributions have been shown to vary between 
tissues [251]. Tissue specific ECM effects are currently being investigated based on the premise 
that tissue specific factors within each tissue’s ECM would have preferential effects for 
restoration of the tissue of origin. M-ECM and C-ECM, possessing muscle specific ECM 
components, may preferentially influence skeletal and/or cardiac muscle tissues.   
87 
Skeletal muscle PVSC differentiation resulted in a complex phenotype with a mixture of 
skeletal and cardiac muscle markers. This is similar to observations of other stem cell types 
during development and early tissue wound healing [252]. The course of early fetal development 
of skeletal muscle has shown both cardiac troponin and fast skeletal muscle myosin heavy chain, 
which are highly cardiac and skeletal muscle specific, respectively, in adult tissues [252]. These 
results have extended to muscle derived stem cell (MDSC) differentiation in vitro, where a mix 
of skeletal and cardiac muscle contractile proteins is observed [252]. Both muscle and non-
muscle ECM treatments increased sarcomeric MHC expression and cell fusion. SIS increased the 
total number of fused cells, whereas M-ECM and C-ECM increased the number of nuclei per 
cell. This may suggest that SIS is most effect for directing early myogenesis, whereas M-ECM 
and C-ECM promotes greater maturity for fusing cells.  
Cardiac PVSCs, however, did not show skeletal muscle differentiation or fusion. This 
lower relative differentiation capacity compared to skeletal muscle PVSCs may be related to the 
differing regenerative capacity of skeletal and cardiac muscle. Skeletal muscle is more able to 
regenerate following injury than cardiac tissue, which leads to scar formation [3]. This lack of 
differentiation competence may be reflected in the PVSC population as well. The present study 
showed that ECM treatment did not alter this lack of differentiation potential. 
ECM treatment did affect the proliferation of skeletal and cardiac muscle PVSCs, 
however. Both skeletal muscle myocytes and cardiomyocytes are considered post-mitotic, 
terminally differentiated cells in adult tissues. As such, differentiation and proliferation are 
opposing processes in that terminal differentiation requires a decrease in proliferation. Skeletal 
muscle regeneration is an archetype of this response, where after skeletal muscle progenitors 
enter a proliferation phase, exit the cell cycle, and fuse to form non proliferating myofibers [39]. 
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It was shown that ECM degradation products, regardless of muscle or non-muscle tissue sources, 
inhibited proliferation in high serum culture conditions without an increase in cell death, as 
shown by similar total cell numbers after treatment. Serum free conditions were then investigated 
to determine whether factors in the ECM directly resulted in this decreased proliferation, or if it 
was due to inhibiting mitogenic pathways from serum stimulation. Under serum free conditions 
however, ECM treatment did not show a dose dependent effect upon proliferation, though C-
ECM induced a reduction in proliferation in skeletal muscle PVSCs and SIS treatment induced a 
slight decrease for cardiac muscle PVSCs. This suggests that anti-proliferative mechanisms are 
present in pepsin derived ECM degradation products that neutralizes mitogens found in serum 
rather than directly affecting the cell cycle. Purified type I collagen showed a similar reduction in 
proliferation which indicates that collagen and/or collagen degradation products, rather than 
small matricryptic molecules cause this effect.  
There are some limitations to the approach taken in the present study. Exposure to an 
ECM digest represents the sum of the numerous individual effects from all of the degradation 
products in the pepsin digest. Specific peptide sequences have been isolated from urinary bladder 
ECM digests, which affected stem cell migration [246]. However, this single peptide represents a 
minute fraction of all of the unique constituent molecules. It is possible that some of these 
molecules have opposing effects, such as chemotactic and chemorepellant effects. Also, pepsin is 
not a physiologic enzyme found during normal wound healing or homeostasis in vivo. 
Physiologic degradation involves many proteases that have far greater cleavage specificity than 
pepsin [243]. Nevertheless, ECM pepsin degradation products have shown activity similar 
activity as in vivo derived products, and are a useful model of ECM degradation. Finally, though 
specific ECM treatments increased skeletal PVSC fusion, this was still an extremely rare event 
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relative to primary myoblast isolates or cell lines. It is unclear whether these differences are 
relevant for PVSC differentiation into skeletal muscle in an in vivo setting. 
In summary, clearly defined tissue specific effects of muscle and non-muscle ECM on 
PVSCs were not consistently observed in vitro. Rather, ECM degradation products from any 
source were effective at improving skeletal muscle PVSC myogenic differentiation as well as 
decreasing skeletal and cardiac PVSC proliferation. The default PVSC differentiation phenotype 
was also non-tissue specific as PVSCs typically were predisposed towards a cardiomyogenic 
lineage, though both skeletal and cardiac differentiation markers were found. These results 
suggest that direct influence of ECM degradation products on PVSC differentiation into skeletal 
or cardiac muscle is not a mechanism of potential tissue specific effects in vivo.  
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4.0  COMPARISON OF ECM SCAFFOLDS PREPARED FROM SKELETAL AND 
CARDIAC MUSCLE FOR TREATMENT OF VOLUMETRIC MUSCLE LOSS IN A RODENT 
MODEL 
4.1 INTRODUCTION 
Extremity volumetric muscle loss (VML) as a consequence of traumatic injury exceeds the 
innate regenerative capacity of skeletal muscle tissue and leads to significant functional 
impairment [10]. Direct or indirect causes of VML include direct trauma (e.g. car accidents and 
gunshot wounds), peripheral compartment syndrome, muscle ischemia, and surgical excision 
[13, 16, 18, 33].  VML is typically debilitating, and associated with decreased quality of life and 
independence [22, 23]. Current treatment strategies for VML are limited. Autologous muscle 
grafting (e.g. free flap transfer) is the standard of care, though this approach presents challenges 
such as limitations in the size of the transferred muscle tissue, engraftment efficiency, and donor 
site morbidity [11, 14, 31, 36]. Implantable synthetic materials have been used for muscle repair 
to reinforce injured muscle and prevent further damage, but the non-degradable polymers 
typically used for such repairs may result in adverse outcomes such as fibrous tissue deposition 
[134, 135, 139]. Therefore, new therapies are needed to not only reinforce damaged muscle, but 
to also promote new muscle formation and functional recovery. 
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 Naturally derived extracellular matrix (ECM) scaffolds have been successfully used to 
promote tissue restoration in a number of pre-clinical and clinical applications [73, 74]. These 
biologic materials are prepared via the decellularization of mammalian tissues to yield acellular 
scaffolds composed of native ECM. This ECM is composed of a diverse range of collagen types, 
glycosaminoglycans, proteoglycans, other bioactive molecules that provide potent biological 
signals to its resident cells. Multiple tissues and organs have been decellularized for use as ECM 
scaffolds, including the heart [180, 202], pericardium [242, 253], vascular tissue [154], skeletal 
muscle [102, 168], liver [148, 254], lung [213, 255], small intestine [194, 256], urinary bladder 
[257, 258], and dermis [235, 241], among many others. The ECM scaffolds derived from these 
various tissues have primarily been implanted in non-homologous locations (e.g. implanting a 
dermal ECM scaffold in a skeletal muscle location for ventral hernia repair). Recently however, 
homologous tissue specific ECM applications have been investigated. Since the ECM of every 
tissue provides its resident cells with a unique microenvironment, characterized by a composition 
and architecture specific to that tissue for structural, mechanical, and biological support, it is 
plausible that a tissue specific ECM scaffold is to use the cues provided in the ECM 
microenvironment to promote site specific remodeling.   
The goal of the present study was to evaluate the efficacy of a skeletal muscle tissue specific 
ECM scaffold to promote functional skeletal myogenesis in a mouse model of VML compared to 
non-skeletal muscle ECM. Skeletal muscle tissue was decellularized using a previously 
described method, and the identical method was applied to cardiac tissue (non-skeletal, striated 
muscle) and small intestinal submucosa (non-skeletal, smooth muscle).   
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4.2 METHODS 
4.2.1 Overview of experimental design 
The same decellularization protocol was utilized to prepare skeletal muscle ECM (M-ECM), 
cardiac ECM (C-ECM), and small intestinal submucosa sheets that were prepared using 
conventional techniques (SIS) or using the muscle ECM protocol (SIS-M). ECM sheets were 
further processed into a particulate form for implantation in a murine quadriceps VML model. 
Each ECM scaffold was used to repair the VML defect, which was evaluated histologically for 
evidence of skeletal muscle myogenesis and remodeling at 14, 56, and 180 days post 
implantation. Functional improvements were characterized at 180 days using electromyography 
(EMG) to determine if there is a difference in functional recovery among the groups.  All 
experiments were conducted with approval of the University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC). 
4.2.2 Tissue decellularization and device preparation 
Psoas major skeletal muscle, cardiac left ventricle free wall, and small intestine tissues were 
obtained from market weight pigs (approx. 100 kg) and decellularized using a modified version 
of a previously established protocol for skeletal muscle ECM. Skeletal and cardiac muscle were 
sliced into 2.2 mm cross sectional sheets (transverse to the longitudinal axis) using a rotating 
blade. Small intestinal submucosa sheets were prepared by isolating the stratum compactum, 
muscularis mucosa, and submucosal from the other layers via mechanical delamination. All 
tissues were then frozen and lyophilized. The dried tissue sheets were delipidized by stirring in a 
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chloroform/methanol solution (2:1 v/v, Sigma) for 30 minutes, followed by a graded series of 
ethanol (100, 100, 95, 70, and 50%) for 30 minutes each and then several water washes. Tissues 
were then frozen until further processing in a spinner flask at 70 RPM. Tissues were 
enzymatically processed with 0.2% Trypsin/0.2% EDTA (Sigma) at 37 °C for 2 hours, and then 
placed in alternating 20 minute hypotonic/hypertonic washes of deionized water and 2X PBS, 
respectively. Detergent treatment with 2% sodium deoxycholate (Sigma) for 5 hours was 
performed to solubilize cell components, followed by another pair of hypotonic/hypertonic 
washes and a fresh change of 2% sodium deoxycholate for 16 hours. A 1% Triton X-100 (pH=8, 
Sigma) solution was used to remove residual deoxycholate for 1 hour, which was followed by 2 
washes in deionized water. Final decellularization was achieved after exposure to 0.1% peracetic 
acid/4% ethanol for 2 hours and residual chemicals removed via extensive washing: 2 washes 
with PBS and  2 washes in deionized water for 30 minutes each, 1X PBS for 16 hours, and 4 
washes in deionized water. The resultant M-ECM, C-ECM, and SIS-M ECM sheets were frozen 
and lyophilized. 
 Three dimensional ECM devices were prepared from ECM sheets as previously 
described [56]. Lyophilized ECM sheets were comminuted into a particulate form using a Wiley 
Mill.  ECM particulate was passed through either 40 or 60 mesh screens and combined at a 2:1 
(40:60 mesh, w/w) ratio. This ECM particulate mix was wetted, fit within a 3 mm thick mold, 
and lyophilized. Devices were then cut to final dimensions of 4x4x3 mm to fill the VML defect. 
ECM devices and sheets were sterilized with ethylene oxide (16 h cycle at 50 °C in a Series 
3plus EOGas Sterilizer, Anderson Sterilizers, Inc. Haw River, NC) prior to implantation. 
94 
4.2.3 Surgical creation of the VML defect and ECM device implantation 
A VML defect was created in the quadriceps of female C57BL/6 mice (age 6 - 8 weeks, Jackson 
Laboratories) as previously described [56] and shown in Figure 29. Mice were anesthetized with 
2% isofluorane and a 1.5 cm incision through the skin and fascia was made to expose the 
quadriceps muscle. The VML defect was created by full thickness excision of the tensor fascia 
latae muscle and partial thickness excision of the underlying rectus femoris (Figure 29), which 
corresponds to the following defect dimensions:  full muscle width x 4 mm (longitudinal)  x 3 
mm deep.  Non-resorbable polypropylene sutures (size 7-0, Oasis, Fisher Scientific) were placed 
along the lower corners of the defect to demarcate defect borders. Defects were either left 
untreated (NTx) or repaired with M-ECM, C-ECM, SIS-M, or SIS particulate devices. The three 
dimensional ECM devices were placed within the VML defect and covered with a 1 x 1 cm 
ECM sheet sutured with polypropylene sutures to adjacent healthy muscle (Figure 30). The 
incision was closed with polyglycolic acid  (PGA) suture (size 7-0, Oasis, Fisher Scientific), and 
animals were allowed to ambulate normally with analgesic (buprenorphine hydrochloride, 0.25 
mg/kg) and antibiotic (enrofloxacin, 20 mg) administration for 3 days post operatively. Animals 
were sacrificed and the treated quadriceps muscle harvested for histologic analysis after 14, 56, 
and 180 days post implantation (n = 4 per device and time point), or for functional 
electromyography (EMG) analysis at 180 days (n = 8 per device). 
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 Figure 29. Schematic representation of the VML model in the mouse quadriceps muscle2. The 
defect (red region) consists of a full thickness resection in the tensor fascia latae muscle and a 
partial thickness resection of the rectus femoris in the mouse hindlimb. A size matched ECM 
particulate device is then implanted within the defect.  
2Adapted from The Laboratory Mouse, first edition, Vladimír Komárek, Gross Anatomy, page 122, Copyright 2004, 
with permission from Elsevier. https://www.elsevier.com/ 
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 Figure 30. Representative images of an SIS particulate device with overlaid sheet within the 
VML defect at the time of implantation. The ECM fills the defect and is held in place with a 
sheet of ECM sutured at the distal and proximal defect borders.  
4.2.4 Histologic analysis of ECM remodeling in a VML defect 
Histologic analysis was conducted on tissues collected at 14, 56, and 180 days post implantation 
to evaluate ECM remodeling and myogenesis. Mouse legs were fixed with 10% neutral buffered 
formalin immediately following sacrifice, and the entire quadriceps muscle isolated, bisected 
along the saggital plane, and sectioned. Fixed tissues were embedded in paraffin and cut into 5 
μm thick sections for Masson’s Trichrome staining or immunolabeling. Defect borders were 
demarcated by the non-resorbable sutures at the edges of the defect.  
 Immunolabeling studies were performed to determine the presence of blood vessels 
(CD31), innervation (βIII tubulin), and myogenesis (fast and slow myosin heavy chain and 
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desmin) within the defect area. Sections were deparaffinized with xylenes and a graded series of 
ethanol prior to immunolabeling and extensive buffer washes conducted between each step 
unless otherwise indicated.  
1. CD31 and βIII tubulin immunolabeling was performed to evaluate the tissue remodeling 
characteristics of angiogenesis and innervation, respectively. Antigen retrieval was conducted in 
sodium citrate (10 mM, Sigma) heated to 95-100 °C for 20 minutes and sections were blocked 
for 1 hour with 1 % bovine serum albumin (BSA, Sigma)/2% horse serum (Gibco) in PBS-T 
(0.1% Triton X-100/0.1% Tween 20, Sigma). Sections were decanted and immediately incubated 
overnight at 4°C  in either CD31 (rabbit polyclonal, ab28364, abcam) or βIII tubulin (mouse 
monoclonal, clone TU-20, MA1-19187, Sigma) primary antibodies diluted (1:100) in the 
blocking solution. AlexaFluor 488 conjugated secondary antibody (anti-rabbit or anti-mouse 
Alexa Fluor-488, Invitrogen) was applied for 2 hours followed by 4’,6-diamidino-2-phenylindole 
(DAPI) nuclear staining. Slides were coverslipped with aqueous mounting media (DAKO) and 
imaged via epifluorescence to determine the presence of blood vessels and nerves around and 
within the ECM device during remodeling.  
2. Fast and slow myosin heavy chain (f/s-MHC) co-labeling was performed to determine the 
presence of mature skeletal muscle as previously described [105]. Antigen retrieval was 
conducted with 0.1 mM EDTA heated to 95-100°C for 25 minutes followed by 0.1% 
Trypsin/0.1% Calcium Chloride (w/v) at 37 C for 10 min. Peroxidase activity and non-specific 
protein binding were  blocked by incubation in 0.3% (v/v) hydrogen peroxide for 10 minutes and 
1% BSA/2% horse serum in TBS (blocking solution) for 30 minutes, respectively. Blocking 
solution was decanted and then immediately incubated with slow MHC primary antibody (mouse 
monoclonal, clone NOQ7.5.4D, M8421, Sigma) diluted in blocking solution (1:4000) for 40 
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minutes. A biotinylated secondary antibody (anti-mouse biotinylated, Vector) diluted in blocking 
solution (1:200) was applied for 1 hour followed by incubation with an avidin-biotin-peroxidase 
complex (Vectastain ABC, Vector) for 30 minutes. A diaminobenzadine substrate (ImmPact 
DAB, Vector) was applied until appropriate staining developed. Sections were incubated in 
blocking solution for an additional 10 minutes and labeled with an alkaline phosphatase 
conjugated primary antibody against fast myosin heavy chain (anti-mouse monoclonal alkaline 
phosphatase conjugated, clone MY-32, A4335, Sigma) diluted in blocking solution (1:200) for 
one hour. Red alkaline phosphatase substrate was applied until appropriate staining developed. 
Slides were counterstained with hematoxylin, dehydrated, and coverslipped.  
3. Desmin labeling for developing muscle and mature muscle was achieved using the same 
protocol for slow MHC as described above in (2), substituting a desmin primary antibody 
(mouse monoclonal, clone DE-U-10, ab6322, Abcam) diluted (1:500) in blocking solution. 
4.2.5 Electromyography (EMG) of innervated muscle in the VML defect 
Electromyography (EMG) measurements were conducted at 180 days to assess functionally 
innervated skeletal muscle formation within the VML defect following ECM remodeling (n = 8 
animals). Muscle electrical activity was recorded with a bipolar silicone epimysial electrode 
inserted within the VML defect along the fascial plane dividing the tensor fascia latae and 
underlying rectus femoris muscle. The recording area of the electrode was in contact with the 
ventral aspect of the defect and was insulated from underlying uninjured muscle by the silicone 
sheet. A pair of 38G Teflon coated fine wire electrodes with deinsulated tips were placed around 
the femoral nerve approximately 1 cm proximal to the defect to stimulate compound muscle 
action potentials in the quadriceps muscle. Stimulation pulses (200 μs anodic phase, 3Hz, 20 s 
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train duration, Model S88X Stimulator, Grass Technologies, Natus Neurology Inc., West 
Warwick, RI) were applied and the resulting compound muscle action potential (CMAP) within 
the defect were averaged and recorded (Tektronix TDS 3012C Digital Phosphor Oscilloscope, 
Tektronix Inc., Aliquippa, PA) after amplification and bandpass filtering (50X gain, 30-3000Hz 
bandpass filter, BMA 400 bioamplifier, CWE Inc., Ardmore, PA). A schematic of the recording 
equipment and electrode placement is shown in Figure 31.  
 
 
Figure 31. EMG recording setup for evaluating muscle function after 180 days. A schematic (A) 
of the recording equipment and electrode placement within the quadriceps muscle and a 
representative image of the electrode placement in situ during testing.  
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 The CMAP was characterized by the peak-to-peak voltage (VPP) and root mean square 
voltage (VRMS) of the response during a time window 1-8 ms following stimulation. Muscle fiber 
recruitment characteristics were determined from the relationship between nerve stimulation 
intensity (0.3-8V) and the CMAP response (VPP and VRMS) [259, 260]. These parameters 
include: (1) the maximum peak-to-peak voltage (VPP-max), (2) the maximum RMS voltage 
(VRMS-max), (3) the stimulation threshold for a CMAP reponse (Sthresh), (4) the stimulation 
required to evoke half the maximal response (S1/2), (5) the minimum stimulation required to 
evoke a maximal CMAP reponse (Smax), (6) and the slope of the linear region of the muscle 
recruitment curve (slope). These parameters correspond to a sigmoidal recruitment curve as 
shown in Figure 32.  
 
 
Figure 32. Representative muscle recruitment curve for uninjured muscle highlighting the 
recruitment parameters evaluated in this study. The thresholds of stimulation were calculated at 
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the minimum, half maximal, and maximal Vpp amplitude of the CMAP response. Muscle 
recruitment rate was calculated as the slope of linear region of the recruitment curve.  
4.2.6 Statistical analysis 
 All values are presented as mean ± standard error. Statistical analysis of VPP-max, VRMS-max,  
Sthresh, S1/2, Smax, and slope was conducted with a Kruskal-Wallis non-parametric analysis of 
variance (ANOVA) with a post-hoc Mann-Whitney U Test and Sidak correction using SPSS 
software (IBM SPSS Statistics v21, IBM Inc., Armonk, NY). A non-parametric analysis was 
chosen after determining that the data did not follow a normal distribution via the Kolmgorov-
Smirnov test for normality. Statistical significance was defined as p < 0.05.  
4.3 RESULTS 
4.3.1 Histologic analysis of ECM remodeling in a VML defect 
Histologic analysis of the remodeling ECM constructs implanted within the VML defect showed 
distinct remodeling differences between groups. Masson’s Trichrome staining showed a robust 
mononuclear cell infiltrate in the periphery after 14 days for each ECM group, which was 
accompanied with disruption of scaffold architecture that is consistent with degradation. The 
scaffold interior was less populated with cells, with more infiltration observed for the M-ECM 
group. The untreated defect was also highly cellular at the defect border. A similar trend was 
observed at the 56 day time point, in which active mononuclear cell remodeling was underway at 
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the periphery. Untreated defects, however, had a greatly reduced cellular infiltrate, replaced 
primarily with adipose and loose connective tissue (Figure 33). After 180 days, additional 
histologic differences were observed. M-ECM had undergone the greatest amount of scaffold 
degradation, with only fragments visible after 180 days (Figure 34). The C-ECM and SIS-M 
groups still had bulk ECM scaffold visible within the defect, which were well cellularized at the 
periphery but not the interior of the scaffold. Untreated defects were similar in appearance to the 
56 day time point maintaining connective tissue near the edge of native muscle and adipose 
tissue filling the remainder of the defect.  
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 Figure 33. Masson’s Trichrome stained images of the VML defect after 56 days. Untreated 
defects (A) were filled with adipose tissue (white tissue) while the ECM devices (B-E, blue) 
were still visible and undergoing the remodeling process. All images are oriented such that 
underlying uninjured quadriceps are along the bottom of each image. Scale bar represents 200 
μm.  
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 Figure 34. Masson’s Trichrome stained images of the VML defect after 180 days. Untreated 
defects (A) were filled with adipose tissue (white tissue) while the ECM devices (B-E, blue) 
were still visible and undergoing the remodeling process. All images are oriented such that 
underlying uninjured quadriceps are along the bottom of each image. Scale bar represents 200 
μm.  
 
Myogenesis within the defect was observed  at a low frequency by the 56 day time point. 
Untreated defects showed few desmin (Figure 35) and myosin heavy chain positive myofibers 
(Figure 36), and these occasional cells were present only directly adjacent to well developed 
muscle at the defect border. Muscle cells were also infrequent in ECM treated defects, though 
105 
these cells were located farther from the defect border. A high proportion of more mature muscle 
at the defect border had centrally located nuclei indicating that these muscle fibers had 
undergone myogenesis.    
 
 
Figure 35. Desmin immunolabeling (brown) within the VML defect after 56 days. Desmin 
expressing cells did not migrate from the defect border in untreated animals (A, positive staining 
represents native tissue), while ECM treatment encouraged desmin positive cell accumulation in 
the area of remodeling near the ECM periphery (B-E). Each ECM image is located several fields 
of view away from the defect border, while the untreated image is located in proximity to the 
border to show that there are no desmin expressing cells migrating from native muscle. Scale bar 
represents 100 μm.  
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 Figure 36. Fast (pink) and slow (brown) skeletal muscle MHC immunolabeling within the VML 
defect after 56 days. MHC expressing cells did not migrate from the defect border in untreated 
animals (A, positive staining represents native tissue), while ECM treatment encouraged desmin 
positive cell accumulation in the area of remodeling near the ECM periphery (B-E). Each ECM 
image is located several fields of view away from the defect border, while the untreated image is 
located in proximity to the border to show that there are no myosin expressing cells migrating 
from native muscle. Scale bar represents 100 μm.  
 
Immunolabeling studies showed the presence of CD31 expressing blood vessels within 
the area of tissue remodeling at both the 14 and 56 day time points (Figure 37). These cells were 
apparent within the peripheral regions of the scaffold, where the cellular infiltration was greatest. 
This was also true for the 56 day time point, though there were fewer blood vessels apparent in 
untreated defects. ECM associated vessels were smaller in size and more numerous at the 14 day 
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time point, with fewer and larger vessels at 56 days, which was typical of the ECM response. βIII 
tubulin expression was observed in remodeling defects after 180 days post implantation. Small 
nerve bundles were found along of the periphery of implanted ECM devices (Figure 37) that was 
similar for each ECM treatment. There were also non-neuronal mononuclear cells expressing 
βIII tubulin occasionally found within the remodeling ECM scaffolds (Figure 38). 
 
 
Figure 37. CD31 expression of blood vessels within the remodeling defect after 14 (A), and 35 
days post ECM implantation. These images are representative of all ECM scaffolds. Scale bar 
represents 100 μm.  
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 Figure 38. βIII tubulin staining (green) of nerve fibers within the area of ECM remodeling. 
Innervation was observed following each ECM treatment including M-ECM (A), C-ECM (B), 
and SIS-M (C). Both transverse (A,C) and longitudinal nerve sections (B) were observed. Cell 
nuclei are labeled with DAPI (blue). Scale bar represents 100 μm.  
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 Figure 39. Representative image of non-neuronal βIII tubulin expression (green, arrows) in 
mononuclear cells within the ECM scaffold. Cell nuclei are labeled with DAPI (blue). Scale bar 
represents 100 μm.  
 
4.3.2 Electromyography (EMG) of innervated muscle in the VML defect 
Electromyography (EMG) of the compound muscle action potential (CMAP) was performed to 
generate muscle recruitment profiles after 180 days post operatively to quantitatively assess 
functionally innervated skeletal muscle in the defect area. Supramaximal nerve stimulation 
produced Vpp-max and VRMS-max values that were greatest in uninjured tissues (9.14 ± 1.02 mV and 
1.88 ± 0.22 mV) and were significantly reduced in untreated defects (2.71 ± 0.63 mV and 0.88 
±0.14 mV), corresponding to approximately 30% and 47% of the uninjured VPP-max and VRMS-max, 
respectively for untreated defects (Figure 39). The greater reduction in peak to peak voltage 
compared to RMS voltage indicates loss of nerve stimulation synchrony in the defect and a 
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broader EMG signal. ECM treatment resulted in supramaximal CMAP amplitudes that were 
increased relative to untreated animals. In order of greatest to least Vpp-max and VRMS-max 
values: M-ECM (6.38 ± 1.24 mV and 1.65 ± 0.30 mV), SIS (5.62 ± 0.97 and 1.36 ± 0.22 mV), 
C-ECM (4.38 ± 0.75 and 1.11 ± 0.15 mV), and SIS-M (3.57 ± 0.46 and 1.09 ± 0.10 mV). 
Though each ECM treatment increased VPP-max and VRMS-max compared to untreated defects, 
differences between ECM scaffolds were not statistically significant from each other (Figure 
40A).  
 
 
Figure 40. Representative waveforms of the CMAP response (A-B) at increasing nerve 
stimulation intensities (0.3-2.0 V for uninjured and 2.0-8.0V for untreated) and the averaged 
recruitment curves for uninjured and untreated VML defects after 180 days. The amplitude of the 
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CMAP waveform at each stimulation intensity was used to generate muscle recruitment curves. 
The initial biphasic wave before 1 ms represents stimulation artifact.  
 
 The untreated VML defect caused a deficiency in muscle recruitment rate as shown in the 
slope of the recruitment curve. Uninjured animals had a recruitment slope of 8.84 ± 2.53 mv/V 
compared to the reduced slope of 0.54 ± 0.15 mV/V for untreated animals. ECM treatment 
resulted in increased recruitment slopes (in order of greatest to least): M-ECM (6.53 ± 2.10 
mV/V), SIS (3.96 ± 1.2 mV/V), C-ECM (2.10 ± 0.75 mV/V), and SIS-M (1.27 ± 0.46 mV/V), 
though only SIS response was statistically increased compared to the untreated control (Figure 
40B).The nerve stimulation thresholds necessary to evoke a minimum, half maximal, and 
maximal responses were also affected by generation of a defect, which was partially recovered in 
ECM treated animals. The generation of a VML defect increased the stimulation voltage required 
to elicit a detectable response with Sthresh of 0.41 ± 0.03 V in healthy animals increased to 4.94 ± 
0.77 V for injured untreated animals. ECM treatment reduced Sthresh to a similar extent for all 
ECM treatment groups, which ranged between 1.36 and 1.6 V. S1/2 and Smax were also increased 
relative to healthy animals, though generally, was not significantly affect by any ECM treatment 
(with the exception of S1/2 for C-ECM. Figure 40C).  
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 Figure 41. Muscle fiber recruitment parameters from EMG recordings of the CMAP within the 
VML defect after 180 days. The amplitude of the CMAP response (A) was calculated as the 
peak-to-peak voltage (VPP) and root mean square voltage (VRMS). Muscle recruitment rate was 
defined as the slope of muscle recruitment during the linear region of the recruitment curve (B). 
Stimulation efficacy (C) was evaluated as the minimum nerve stimulation intensity required to 
evoke a minimum threshold, half maximal, and maximal amplitude response from the 
recruitment curve. Statistically significant differences from untreated animals as determined by 
Kruskal-Wallis non-parametric analysis of variance (ANOVA) with a post-hoc Mann-Whitney U 
Test and Sidak correction (p  < 0.05) are denoted with (*). No significant differences were found 
between ECM treatment groups or healthy animals.  
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4.4 DISCUSSION 
The present study compared tissue specific ECM scaffolds prepared from skeletal and cardiac 
muscle to non-muscle small intestine derived ECM in their capacity promote functional 
restoration in a murine VML injury model. ECM particulate devices were implanted in surgically 
created VML defects for evaluation over a time course of 14, 56, and 180 days post implantation. 
ECM remodeling was characterized histologically at each time point, and muscle function was 
evaluated using EMG after 180 days. 
ECM scaffolds are a clinically utilized biomaterial in numerous tissue reconstruction 
applications [74]. The widespread use of these scaffolds is due to the favorable remodeling 
response following implantation in sites of injury, where they are rapidly degraded and replaced 
with site specific host tissue [73, 207]. Though ECM scaffolds may be isolated from virtually 
any tissue, it is unknown how the source tissue affects the remodeling response. The tissue 
specific ECM scaffold hypothesis postulates that an ECM scaffold isolated from the same tissue 
it is intended to treat will lead to the optimal remodeling response because it contains the ideal 
microenvironmental factors for that tissue. Tissue specific ECM properties have been 
characterized and compared across many decellularized tissues, and in vivo applications of tissue 
specific scaffolds have shown promise in treating injured organs such as the heart [123, 192, 
203], lung [88], and liver [85] using heart, lung, and liver ECM, respectively.  This success has 
prompted studies characterizing and comparing homologous vs. non-homologous ECM scaffold 
implementation in vivo and in vitro, but an often overlooked variable is the effect of the 
decellularization methods used to isolate the ECM. Adequate decellularization is necessary to 
avoid an adverse immune response [129, 261], and so decellularization standards have been 
established to ensure that excess cellular material has been removed from the tissue [74]. 
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However, every decellularization treatment inevitably affects ECM structure and/or composition, 
and this phenomenon has been previously shown for multiple ECM scaffolds [181, 241].  
Removal of ECM sequestered growth factors and partial protein denaturation are common 
sequelae of decellularization methods that involve strong ionic detergents, enzymes, or organic 
solvents, which are necessary to fully decellularize certain tissues [241]. Distinctive tissue 
characteristics, such as diffusion and mechanical properties, often necessitate tissue specific 
decellularization strategies. This creates difficulties in directly comparing ECM derived from 
different tissues because the ECM scaffold is a product of both the decellularization method as 
well as its source tissue.  
Several previous studies have investigated M-ECM for use as a tissue specific scaffold 
for muscle repair. The results of these studies have been mixed, and a clear advantage for an M-
ECM scaffold over non-muscle scaffolds for in vivo VML repair has not yet been established 
[176-178]. The outcome of several series of studies has shown minimal myogenesis after 
acellular M-ECM implantation for muscle repair. However, myogenic potential and functional 
improvements were realized for these scaffolds when seeded and cultured with stem cells prior to 
implantation [92, 93, 101]. These prior studies have either not compared M-ECM to non-muscle 
ECM, or have not controlled for the effect of the decellularization method by using the same 
muscle decellularization method on the non-muscle tissue. The present study is the first 
comparison of a non-muscle (small intestinal derived ECM) that is decellularized using the same 
method as M-ECM such that the only difference between the scaffolds is the source tissue.   
This is also the first report that extends the tissue specific hypothesis to cardiac tissue. 
Though both skeletal and cardiac muscle are striated muscle tissues, they have very different 
injury responses. Skeletal muscle has a well characterized, highly regenerative response to 
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injury. It is only when the injury is of a relatively large critical size, such as in VML, that these 
natural regeneration mechanisms are unable to compensate [10, 56, 177]. This high capacity to 
recover after injury is in large part due to the abundant resident stem cell population, the satellite 
cell, and it’s robust capacity to proliferate and differentiate into de novo muscle fibers. Cardiac 
tissue in contrast does not possess a similar resident stem cell or regenerative capacity, and its 
injury response is characterized by fibrosis and progressive loss of function over time [3]. 
Whether the native cardiac ECM component plays a role in this response remains unknown. It 
was also unknown how the cardiac ECM would perform when transplanted into a regenerative 
location such as skeletal muscle, and if the cardiac ECM is sufficiently distinct to initiate a 
different remodeling outcome. The results of this study do not demonstrate a difference between 
C-ECM and M-ECM scaffolds, indicating similar potential of these ECM sources.  
Several remodeling characteristics were affected by ECM treatment. Implantation of each 
ECM scaffold was accompanied by rapid infiltration with mononuclear cells and angiogenesis, 
which is consistent with previous studies of ECM mediated muscle repair. This remodeling 
effect persisted until the final 180 day time point, in which scaffold remnants and high cellularity 
were still observed. There were some notable differences between ECM groups. The muscle 
ECM, though similar in appearance to other groups at both early time points, was more degraded 
than C-ECM and SIS-M after 180 days. The M-ECM group also corresponded to greater 
cellularity, though there were no observed differences in angiogenesis or innervation. M-ECM 
and C-ECM groups also presented a greater number of desmin and myosin heavy chain positive 
myofibers within the remodeling defect than SIS-M. Untreated defects, in contrast, appeared to 
have fully remodeled with only loose connective tissue and adipose tissue by the 56 day time 
point, which was also the response after 180 days. 
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An important outcome when evaluating muscle repair, is the in vivo effect on the 
restoration of muscle function. Functional muscle tissue cannot be assessed solely on histologic 
observation, since multiple events must occur in addition to muscle cell formation. Muscle fiber 
alignment, mature nerve formation, and neuromuscular junction formation are muscle repair 
processes that are necessary for muscle tissue to produce usable force [39]. The present study 
performed EMG recordings within the VML defect as a method of evaluating muscle function, 
which accounts for mature muscle formation as well as innervation under nervous system 
control. Therefore, EMG analysis only measures mature muscle that has also been functionally 
innervated. Innervation is necessary for not only proper function, but also for survival of the 
skeletal muscle, and cannot be confirmed by histologic methods alone. The present study showed 
that muscle and non-muscle ECM treatments were similarly effective in improving muscle 
recruitment metrics including the amplitude of the response (VPP and VRMS) and the threshold of 
stimulation. The maximum amplitude is the result of the total muscle activity evoked by 
supramaximal stimulation and is correlated to the total amount of innervated muscle present 
within the recording area. Increased muscle activity may be the result of either increased 
myogenesis and  innerveration and/or improved survival of surrounding muscle fibers following 
defect creation since the electrodes were placed in the same anatomic location for each animal. 
Stimulation threshold is related the efficacy of stimulation, and larger diameter nerves have a 
lower threshold of applied electrical stimulation and correspondingly. The lowered threshold 
could be the result of an increased number of myofibers available for generation of a detectable 
response rather than nerve diameter. EMG provides a quantitative assessment of muscle function 
that is dependent on both muscle and nerve function, but it is not necessarily correlated with 
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force production. Muscle alignment, ECM attachment, and continuity with adjacent muscle 
fibers are all factors that will affect force production and are not detectable with EMG.  
Multiple histologic and EMG characteristics are improved with ECM treatment compared 
to an untreated VML defect. The functional results of each ECM treatment, though an 
improvement over non-treated animals, were not statistically different from each other. There 
may have been a trend for improved EMG responses for M-ECM, though this was not 
significant. Also, the degree of improvement was likely small relative to non-muscle ECM and 
would not justify its use over clinically available non-muscle ECM such as SIS.  
The ECM device preparation method used in the present study (i.e. molded ECM 
particulate devices) fully disrupted the native three dimensional structure of the ECM. This 
approach has been shown to be useful for two dimensional ECM (such as SIS sheets) that would 
not otherwise fill a three dimensional defect [56, 105, 195]. However, these methods may 
abrogate the instructive structural and mechanical cues in the ECM microenvironment and 
cannot be discounted. Even the M-ECM and C-ECM processing methods used in the present 
study substantially changed ECM structure. Cross-sectional sheets, though preserving microscale 
architecture, could not recapitulate the continuous tubular basement membrane structure found in 
native muscle ECM. The advantage to using a particulate device is that all ECM devices are able 
to be prepared in the same manner, controlling for architectural differences. The present study 
therefore isolated the effects of composition differences between ECMs, rather than structure.  
Since robust differences between ECMs from different tissue sources were not observed 
in vivo, ECM structure may indeed play a significant role in the host response, necessitating 
future studies that examine ECM scaffolds with minimally disrupted architecture. Whole organ 
decellularization is currently the most effective method for preserving structure. Perfusion 
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methods have already been described for cardiac decellularization [151, 179, 202], though 
skeletal muscle is more challenging. Unlike the heart, which has natural large diameter 
inlets/outlets for perfusion (e.g. the aorta and pulmonary artery); skeletal muscle circulation is 
supported by multiple small vessels. The collateral circulation in skeletal muscle is advantageous 
in living tissue by enabling rapid increases in transport during high metabolic activity and 
allowing other vessels to compensate during infarction, but it presents a challenge for perfusion. 
Such small vessels are numerous and difficult to cannulate due to their small diameter 
(unpublished observations). Furthermore, while the heart is a compartmentalized organ, skeletal 
muscle has insertion points where perfusion solution may leak if it is dissected from the bone. As 
a result, there have been no descriptions of perfusion decellularized skeletal muscle to date. 
Intact skeletal muscle ECM has been prepared via immersion decellularization in rodents, 
primarily due to the small size of these tissues. Diffusion limitations make immersion 
decellularization ineffective for large animal muscle tissue sources, limiting clinical potential. 
The present study investigated porcine tissue, since this is the species used in many clinical 
products [74], including the commercially available SIS scaffold. Though, the structural 
contributions of muscle ECM can potentially be investigated in rodent animal models, novel 
methods of whole muscle decellularization would be needed in order to translate these results to 
large animal models and humans.  
A limitation of the present study is the assumption that the decellularization treatments 
have equivalent effects upon the matrix structure and composition. The same tissue differences 
that necessitate different decellularization methods may also affect ECM exposure to each 
chemical. Therefore, small intestinal ECM, in which mild treatment is adequate for positive 
remodeling responses, may be more greatly affected than a dense tissue such as skeletal and 
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cardiac muscle. The chemicals required to decellularize muscle tissue is potentially a limitation 
in itself. The strong detergents and enzymatic treatments, though necessary for adequate cell 
removal, may remove factors in the matrix that are vital for a tissue specific response. In other 
words, the ECM scaffolds resulting from decellularization with the muscle ECM method may be 
too similar in composition due to removal of muscle specific factors to observe a difference. 
Another limitation of the present study is that remodeling had not yet concluded for all treatment 
groups. The C-ECM, SIS-M, SIS, and to a lesser extent M-ECM, all had visible scaffold 
remnants remaining on histologic analysis. This suggests that ECM degradation and remodeling 
has not concluded, and further functional improvements may be apparent at later time points. 
Previous studies have shown that remodeling and maturation of new muscle tissue can occur 
after the ECM has appeared to have fully degraded histologically [105, 107]. It is also unknown 
how gait biomechanics were affected by each treatment. Gait characteristics are not only a 
functional outcome, but may also affect remodeling. For example, if mice tend to unload their 
injured hindlimb in a particular treatment group due to pain or weakness, this would change the 
biomechanical forces felt by the area of remodeling. Previous studies have shown that 
mechanical loading environment greatly affects ECM remodeling outcome [75] 
This aim has established that ECM implantation results in functional improvement after 
VML injury. ECM scaffolds are infiltrated by host mononuclear cells, are vascularized and 
innervated along the periphery, and encourage the formation of islands of skeletal muscle. 
Conclusive tissue specific effects were not observed, with each scaffold having similar effects on 
function as determined by EMG analysis. Nuanced differences in remodeling were observed, 
such as increased degradation for M-ECM scaffolds, though this did not result in a significant 
improvement from other ECM scaffolds.  
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5.0  SYNOPSIS, CONCLUSIONS, AND FUTURE DIRECTIONS 
5.1 SYNOPSIS 
The work presented in this dissertation characterized the composition, in vitro stem cell 
response, and in vivo remodeling characteristics of skeletal and cardiac muscle ECM for use as a 
bioinductive scaffold to restore functional muscle tissue after injury. The hypothesis of this study 
stated that the microenvironmental factors present in a muscle ECM scaffold would subsequently 
provide muscle specific signals and positively influence functional restoration following injury 
to a greater extent than a non-muscle scaffold. This was extended to both skeletal and cardiac 
ECM sources to determine whether striated muscle ECM in general possesses similar capacity to 
promote functional recovery. The effect of the muscle decellularization method upon the matrix 
was evaluated by comparing the muscle protocol to a milder method, which is sufficient for 
small intestinal submucosa decellularization only.  
The first aim of this study was to develop a method of skeletal muscle decellularization 
from a large animal source that: (1) attained full decellularization according to previously 
established criteria, and (2) retained ECM specific components. This objective was achieved by 
chemically decellularizing skeletal muscle sheets using primarily trypsin, sodium deoxycholate, 
triton X-100, and peracetic acid. The resultant M-ECM contained only small amounts of low 
molecular weight DNA fragments, while preserving ECM components such as elastin, 
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glycosaminoglycans, growth factors, fibronectin, Types I, III, and IV collagen, and laminin. The 
M-ECM scaffold supported muscle progenitor cell growth in vitro and facilitated a constructive 
remodeling response in vivo. This decellularization method was also successfully applied to 
cardiac muscle and small intestinal submucosa, which preserved ECM biochemical and 
structural factors to a similar extent as M-ECM. SIS (decellularized with a single chemical 
exposure) retained the greatest proportions of these factors, confirming that the M-ECM method 
is more disruptive to the native ECM. 
The second aim sought to characterize the effect of degradation products produced from 
muscle and non-muscle ECM scaffolds on PVSC proliferation and differentiation. PVSCs were 
isolated from both skeletal and cardiac muscle tissues; and thus each was derived from a skeletal 
or cardiac ECM microenvironmental niche. In the absence of serum mitogens in the culture 
medium, ECM degradation products from any source did not significantly affect PVSC 
proliferation in a tissue specific manner. Also, all ECM treatments were shown to inhibit 
proliferation in the presence of serum in the media. Following differentiation, PVSCs from 
skeletal muscle exhibited an immature myogenic phenotype, expressing both skeletal and cardiac 
muscle markers. ECM degradation products, but not Type I collagen, increased skeletal muscle 
PVSC differentiation in a non-tissue specific manner. Cardiac PVSCs did not effectively 
differentiate past an early cardiac phenotype, and did not respond to any ECM treatment.  
The third and final aim characterized ECM remodeling in a murine model of VML. 
Implanted ECM underwent a remodeling process that included mononuclear cell infiltration 
within the ECM, degradation, angiogenesis, innervation, and early myogenesis. M-ECM was 
shown to cellularize and degrade more quickly on histologic evaluation than all other ECM 
scaffolds. ECM treatment improved the amount and stimulation capacity of skeletal muscle 
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within the VML defect compared to untreated animals as determined with EMG. However, there 
were not significant differences between different ECM types.  
5.2 CONCLUSIONS 
The results of this dissertation do not support the hypothesis that a tissue specific M-ECM 
scaffold provides a positive benefit for muscle restoration applications. The decellularization 
method developed in this dissertation was effective at retaining ECM components relevant to 
muscle, though these did not influence tissue specific PVSCs in vitro or differentially affect 
functional recovery of a VML injury in vivo. Non-tissue specific ECM scaffolds composed of 
small intestinal submucosa are adequate to promote functional muscle remodeling. 
5.3 FUTURE DIRECTIONS 
Though tissue specific effects were not observed in skeletal muscle tissue, there are other 
potential applications that would be relevant for skeletal and cardiac muscle repair as described 
below.  
5.3.1 Hydrogel formulations of M-ECM and C-ECM 
Injectable, in situ polymerizing hydrogels are being used with increasing frequency for 
biomedical applications such as cell delivery, drug delivery, and/or as a scaffold for 
reconstruction of injured tissue [262]. Injectable hydrogels have several desirable features for 
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therapeutic applications including targeted delivery by minimally invasive techniques, ease of 
repeated delivery, ability to quickly fill an irregularly shaped space, and polymerization to form a 
support structure suitable for host cell infiltration and remodeling. Most of the investigated 
injectable hydrogels have been synthetic polymers with defined structural, chemical, and 
mechanical properties finely tuned for a desired application. However, there have been a number 
of recent descriptions of injectable hydrogels derived from naturally occurring biologic materials 
with purported superior biocompatibility and bioactivity compared to their synthetic 
counterparts. Common constituents of biologic hydrogels include Type I collagen, hyaluronic 
acid, or other proteins such as laminin as found in Matrigel [263].  
It has been shown that biologic scaffold materials composed of the extracellular matrix 
(ECM) of decellularized tissues can be partially digested with pepsin, solubilized, and 
polymerized in situ to form a hydrogel [114, 120, 175, 250, 253, 264-266]. Intact ECM scaffold 
materials retain numerous molecular constituents found in the native tissue such as cell adhesion 
proteins, growth factors [223], and glycosaminoglycans and these materials support a 
constructive, site appropriate, remodeling response when implanted in a variety of anatomic sites 
including skeletal muscle [105, 107, 108], cardiac tissue [117], and the peripheral nervous 
system [267]. It is possible that a hydrogel formed from enzymatically degraded and solubilized 
ECM may maintain some of the biologic activity found in the intact ECM. 
 Both M-ECM and C- ECM hydrogels may be prepared from ECM degradation products. 
C-ECM in particular, may be prepared from tissue slices or from intact porcine heart ECM 
(Figure 41). Hydrogel formation occurs rapidly for these materials resulting in a highly hydrated, 
viscoelastic material. These mechanical properties have been characterized for M-ECM and 
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compared to UBM using parallel plate rheometry to determine the kinetics of gelation (Figure 
42A) and viscoelastic nature (Figure 42B,C) of the hydrogel. 
 
Figure 42. C- ECM (A) was prepared by decellularizing intact porcine hearts and then by 
performing pepsin digestion to prepare degradation products, which could then be used to create 
a C-ECM hydrogel (B) when brought to physiologic pH and temperature in vitro.  
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 Figure 43. Rheological characterization of the mechanical properties of M-ECM and UBM 
hydrogels over time (A) and with varying shear stress frequency (B,C). Pepsin digested ECM 
was neutralized and brought to 37°C at time 0, and after a brief lag phase, storage modulus (G’) 
rapidly increases, indicating hydrogel formation. The storage and loss modulus (G’’) was then 
characterized over a range of oscialltory shear strain frequencies.  
5.3.2 ECM/Synthetic “biohybrid” devices for cardiac repair 
The in vivo portion of this study compared muscle ECMs in a skeletal muscle injury location 
only. The logical corollary to this work would involve a determination of ECM tissue specificity 
in a cardiac repair model. As described previously, the cardiac wound healing environment is 
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very different from skeletal muscle, and may respond in a different manner to ECM. 
Furthermore, this allows direct testing of C-ECM in a cardiac location as compared to M-ECM 
using these same decellularization methods.  
One such application is the development and use of tissue specific ECM biohybrid 
devices. Such devices are composed of both synthetic polymers and ECM scaffolds. The 
objective in developing these materials is to combine the advantages of synthetic materials, such 
as highly controllable mechanical properties, with the biologic activity inherent to the ECM. This 
approach has already tested for electrospun poly(ester urethane)urea (PEUU)/ECM hydrogel 
materials. [100, 265, 268]. PEUU is a biodegradable, elastomeric polymer that has been 
successfully incorporated with UBM and dermal ECM hydrogels, which improves in vivo 
remodeling characteristics such as cellular infiltration compared to the acellular polymer device. 
Preliminary studies are underway to fabricate C-ECM/PEUU hybrid scaffolds for use as a 
cardiac patch for support following MI (Figure 43). The electrospinning conditions have been 
optimized to provide anisotropic behavior matching native heart tissue, which has been shown to 
provide improved cardiac functional outcomes.  
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 Figure 44. An ECM-PEUU biohybrid device for cardiac repair. (A) PEUU was electrospun 
concurrently with electrosprayed dermal ECM pepsin digest, which formed an ECM hydrogel 
component of the device. (B) Electrospinning parameters were optimized to provide anisotropic 
biaxial mechanical properties such as those seen in the native heart.  Images and mechanics 
courtesy of a collaboration with Dr. Antonio D’Amore and the Wagner lab.  
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APPENDIX A 
IMAGEJ SCRIPT USED FOR BRDU QUANTIFICATION 
//BrdU well counter v2.txt 
//author: Matt Wolf 
//Version 2. 7-1-13 
 
   
  dir1 = getDirectory("Choose Source Directory ");  
  list = getFileList(dir1); 
  setBatchMode(true); 
 
//get inputs------------------------------------------------------------------------------- 
  Dialog.create("Well Counter Inputs for RGB Images"); 
 
  Dialog.addMessage("\nThe parameters below need to be manually tested and validated for each 
batch of staining. The blue channel is assumed to be nuclear. \nAll images in a group must be 
imaged using the same fluorophores and exposure times. Each folder of images requires a 
positive control image. Negative controls are recommended."); 
 
  Dialog.addMessage("1. Enter Channels to be analyzed. \n Blue, Green, or Red"); 
  Dialog.addCheckboxGroup(1,3,newArray("Red","Green","Blue"),newArray(false,true,true)); 
 
  Dialog.addMessage("1. Enter the ball radius (px) for background correction. \n Radius must be 
greater than the radius of the largest object that is not background. (staining, exposure time, and 
focus may alter image size) \n100X DAPI stained nuclei have an approximate max radius of 7-
12 px."); 
  Dialog.addNumber("Ball Radius:", 15,0,8,"px"); 
 
  Dialog.addMessage("2. Apply Gaussian Blur and Watershed? \n Watershedding will split up 2 
objects that touch each other, and gaussian blur prevents oversplitting."); 
  Dialog.addCheckbox("Apply blur and watershed?", true); 
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  Dialog.addMessage("3. Enter the automatic thresholding method \nFrom least to most strict: 
Huang, Li, IsoData, Otsu"); 
  Dialog.addChoice("Thresholding Method:", newArray("Li", "Huang", "IsoData", "Otsu")); 
 
  Dialog.addMessage("4. Enter the upper/lower limit for the size of the object. \n Objects 
smaller/larger than this value are ignored. 100X DAPI stained nuclei have an approximate area 
of 100-500 px^2 after blurring and thresholding"); 
  Dialog.addNumber("Minimum Size:", 50,0,8,"px^2"); 
  Dialog.addNumber("Maximum Size:", 3000,0,8,"px^2"); 
 
  Dialog.addMessage("5. Enter the lower limit (between 0 and 1.0) for the circularity of the 
object. \n Objects below this circularity are ignored. 1.0 indicates a perfect circle."); 
  Dialog.addNumber("Minimum Circularity:", 0.7,2,8,""); 
 
  Dialog.addMessage("6. Show Outlines? \n Will save the masked image with each counted 
object numbered."); 
  Dialog.addCheckbox("Show and save outlines?", true); 
 
  Dialog.show(); 
 
// user inputs defined--------------------------------------------------------------------- 
  redchan = Dialog.getCheckbox(); 
  greenchan = Dialog.getCheckbox(); 
  bluechan = Dialog.getCheckbox(); 
  balla = Dialog.getNumber(); 
  blurshed = Dialog.getCheckbox(); 
  threshtype = Dialog.getChoice(); 
  lowsize = Dialog.getNumber(); 
  hisize = Dialog.getNumber(); 
  lowcirc = Dialog.getNumber(); 
  outliner = Dialog.getCheckbox(); 
 
//generate threshold from control---------------------------------------------------------- 
   showMessage("Select a positive control image to set threshold limits"); 
   open(); 
   controlimage = getTitle(); 
   run("Split Channels"); 
 
   selectImage(1); 
   if (redchan==1){  
        run("Enhance Contrast", "saturated=0.5 normalize"); 
        run("Subtract Background...", "rolling=" + balla);  
    if (blurshed==true) run("Gaussian Blur...", "sigma=2"); 
    setAutoThreshold(threshtype + " dark"); 
    getThreshold(RedMin, RedMax); 
    resetThreshold;} 
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   else { 
 RedMin = "NA"; RedMax = "NA";}   
 
   selectImage(2); 
   if (greenchan==1){ 
    run("Enhance Contrast", "saturated=0.5 normalize"); 
    run("Subtract Background...", "rolling=" + balla);  
    if (blurshed==true) run("Gaussian Blur...", "sigma=2");  
    setAutoThreshold(threshtype + " dark"); 
    getThreshold(GreenMin, GreenMax); 
    resetThreshold;} 
   else { 
 GreenMin = "NA"; GreenMax = "NA";} 
 
   selectImage(3); 
   if (bluechan==1){ 
    run("Enhance Contrast", "saturated=0.5 normalize equalize"); 
    run("Subtract Background...", "rolling=" + balla);  
    if (blurshed==true) run("Gaussian Blur...", "sigma=2");  
    setAutoThreshold(threshtype + " dark"); 
    getThreshold(BlueMin, BlueMax); 
    resetThreshold;} 
   else { 
 BlueMin = "NA"; BlueMax = "NA";} 
 
//show parameters used during analysis--------------------------------------------------------- 
   print("control image used:" + controlimage + "\nrolling ball radius = " + balla + "\nblur and 
watershed? = " +  blurshed + "\nthresholding method = " + threshtype + "\nlower particle size 
limit = " + lowsize + "\nupper particle size = " + hisize + "\nlower limit of circularity = " + 
lowcirc + "\nRed lower threshold = " + RedMin + "\nRed upper threshold = " + RedMax + 
"\nGreen lower threshold = " + GreenMin + "\nGreen upper threshold = " + GreenMax + "\nBlue 
lower threshold = " + BlueMin + "\nBlue upper threshold = " + BlueMax); 
   run("Close All"); 
   
//analyze each image in directory------------------------------------------------------------- 
  for (i=0; i<list.length; i++) { 
     showProgress(i+1, list.length); 
     open(dir1+list[i]); 
     wellcounter(); 
     run("Close All"); 
  } 
 
//primary function to count each image---------------------------------------------------------- 
  function wellcounter() { 
 
  run("Split Channels"); 
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//image preprocessing, thresholding, and counting for each channel------------------------------------
---------------------------------------- 
  if (greenchan==1){ 
   selectImage(2); 
   run("Enhance Contrast", "saturated=0.5"); 
   run("Subtract Background...", "rolling=" + balla);  
   if (blurshed==true) run("Gaussian Blur...", "sigma=2");  
   setThreshold(GreenMin, GreenMax); 
   run("Convert to Mask"); 
   resetThreshold(); 
   if (blurshed==true) run("Watershed"); 
   imagename2 = getTitle();   
   if (outliner==false) { 
      run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=Nothing summarize"); 
          } 
   else { 
    run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=[Overlay Masks] summarize"); 
      OutlineDir= dir1 + "\Outlines\\"; 
      File.makeDirectory(OutlineDir); 
      saveAs("JPEG", OutlineDir + imagename2 + "-outline.tif"); 
        } 
  } 
 
  if (bluechan==1){ 
   selectImage(3); 
   run("Enhance Contrast", "saturated=0.5 equalize"); 
   run("Subtract Background...", "rolling=" + balla);  
   if (blurshed==true) run("Gaussian Blur...", "sigma=2");  
   setThreshold(BlueMin, BlueMax); 
   run("Convert to Mask"); 
   resetThreshold(); 
   if (blurshed==true) run("Watershed"); 
   imagename3 = getTitle(); 
   if (outliner==false) { 
      run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=Nothing summarize"); 
          } 
   else { 
     run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=[Overlay Masks] summarize"); 
     OutlineDir= dir1 + "\Outlines\\"; 
     File.makeDirectory(OutlineDir); 
     saveAs("JPEG", OutlineDir + imagename3 + "-outline.tif"); 
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   } 
   } 
 
 //colocalization of green and blue 
  if (bluechan==1 && greenchan==1){    
    imageCalculator("and create",2,3); 
    if (outliner==false) { 
       run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=Nothing summarize"); 
        } 
   else { 
       run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=[Overlay Masks] summarize"); 
       OutlineDir= dir1 + "\Outlines\\"; 
       File.makeDirectory(OutlineDir); 
       imagename23 = getTitle(); 
       saveAs("JPEG", OutlineDir + imagename23 + "-green blue colocal outline.tif"); 
              } 
       } 
 //colocalization of red and blue 
  if (bluechan==1 && redchan==1){    
    imageCalculator("and create",1,3); 
    if (outliner==false) { 
       run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=Nothing summarize"); 
        } 
   else { 
       run("Analyze Particles...", "size=" + lowsize + "-" + hisize + " circularity=" + 
lowcirc + "-1.00 show=[Overlay Masks] summarize"); 
       OutlineDir= dir1 + "\Outlines\\"; 
       File.makeDirectory(OutlineDir); 
       imagename13 = getTitle(); 
       saveAs("JPEG", OutlineDir + imagename13 + "-red blue colocal outline.tif"); 
              } 
       } 
 
} 
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